

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

LUCA BRAMBILLA ET AL.

Serial No.: 10/758,515

Filed: January 15, 2004

For: PRODUCTION OF HETEROLOGOUS  
PROTEINS FROM ZYGOSACCHAROMYCES  
BAILII

Group Art Unit: 1636

Examiner: Maria Marvich

Attorney Docket: 2027.633082/RFE  
(2006330)

**CUSTOMER NO. 23720**


**DECLARATION OF DANILO PORRO  
UNDER 37 C.F.R. § 1.131**

Daniilo Porro states as follows:

1. I am one of the inventors of the above-identified patent application.
2. Prior to November 1, 1998, I was a professor at the Università degli Studi di Milano, Milan, Italy. Since November 1, 1998, I have been a professor at the Università degli Studi di Milano-Bicocca, also in Milan. Since 2003, I have been the president of the Educational Committee for Biotechnology at the Università degli Studi di Milano-Bicocca.
3. Exhibit 1, attached hereto, is a copy of PCT Published Patent Application WO99/14335, reporting work done at my direction between January 1, 1996 and the PCT filing date of September 11, 1998.
4. The work reported in Exhibit 1 was performed in my laboratory at the Università degli Studi di Milano, Milan, Italy.

5. At p. 42, line 21 to p. 43, line 8 of Exhibit 1, we report the transformation of *Zygosaccharomyces bailii*, ATCC 36947 and ATCC 60483, with a pLAT-ADH vector comprising a gene encoding bovine lactate dehydrogenase under the control of the *Saccharomyces cerevisiae* ADH1 promoter (p. 33, lines 9-25). The references to "ATTC36947" and "ATTC60483" at p. 42, line 23 are typographical errors.
6. At p. 47, lines 11-29 of Exhibit 1, we report the transformed *Z. bailii* referred to above were grown on suitable media.
7. At p. 55, Table 3A, we report the quantification of lactic acid we recovered from the transformed *Z. bailii* grown as referred to above.
8. Therefore, Exhibit 1 indicates that, on or before September 11, 1998, we reduced to practice a process for the production of a heterologous protein, comprising culturing a *Z. bailii* transformed with an expression vector comprising a gene coding for a protein and recovering the protein.
9. I declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

20 December, 2004


  
\_\_\_\_\_  
Danilo Porro



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/53, 9/04, C12P 7/56 // C12N 15/31, C07K 14/395	A1	(11) International Publication Number: <b>WO 99/14335</b> (43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number: PCT/EP98/05758 (22) International Filing Date: 11 September 1998 (11.09.98) (30) Priority Data: MI97A002080 12 September 1997 (12.09.97) IT (71) Applicant (for all designated States except US): A.E. STALEY MANUFACTURING COMPANY [US/US]; 2200 E. Eldorado Street, Decatur, IL 62521 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PORRO, Danilo [IT/IT]; (IT). BIANCHI, Michele [IT/IT]; (IT). RANZI, Bianca, Maria [IT/IT]; (IT). FRONTALI, Laura [IT/IT]; (IT). VAI, Marina [IT/IT]; (IT). WINKLER, Aaron, Adrian [NL/IT]; (IT). ALBERGHINA, Lilia [IT/IT]; Via Gaspare Gozzi, 8, I-20129 Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: YEAST STRAINS FOR THE PRODUCTION OF LACTIC ACID



(57) Abstract

Yeast strains transformed with at least one copy of a gene coding for lactic dehydrogenase (LDH) and further modified for the production of lactic acid with high yield and productivities, are described.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### YEAST STRAINS FOR THE PRODUCTION OF LACTIC ACID

The invention refers to yeast strains transformed with at least one copy of a gene coding for lactic dehydrogenase (LDH) and further modified for the production of lactic acid with high yield and productivity.

#### Background of the invention

The applications of lactic acid and its derivatives encompass many fields of industrial activities (i.e., chemistry, cosmetic, and pharmacy), as well as important aspects of food manufacture and use. Furthermore, today there is growing interest in the production of such an organic acid to be used directly for the synthesis of biodegradable polymer materials.

Lactic acid may be produced by chemical synthesis or by fermentation of carbohydrates using microorganisms. The latter method is now commercially preferred because microorganisms have been developed that produce exclusively one isomer, as opposed to the racemic mixture generated by chemical synthesis. The most important industrial microorganisms, such as species of the genera Lactobacillus, Bacillus, and Rhizopus, produce L(+)-lactic acid. Production by fermentation of D(-)-lactic acid or mixtures of L(+)- and D(-)-lactic acid are also known.

During a typical lactic acid fermentation, there is an inhibitory effect caused by lactic acid produced on the metabolic activities of the producing microorganism. Besides the presence of lactic acid, lowering the pH value also inhibits cell growth and metabolic activity.

## 2

As a result, the extent of lactic acid production is greatly reduced.

Therefore, the addition of  $\text{Ca}(\text{OH})_2$ ,  $\text{CaCO}_3$ ,  $\text{NaOH}$ , or  $\text{NH}_4\text{OH}$  to neutralise the lactic acid and to thereby  
5 prevent the pH decrease is a conventional operation in industrial processes to counteract the negative effects of free lactic acid accumulation.

These processes allow the production of lactate(s) by maintaining the pH at a constant value in the range of  
10 about 5 to 7; this is well above the  $\text{pK}_a$  of lactic acid, 3.86.

Major disadvantages are connected to the neutralisation of lactic acid during the fermentation. Mainly, additional operations are required to regenerate  
15 free lactic acid from its salt and to dispose of or recycle the neutralising cation; this is an expensive process. All the extra operations and expense could be eliminated if free lactic acid could be accumulated by microorganisms growing at low pH values, thus minimising  
20 the production of lactate(s).

It has been proposed the use of recombinant yeasts expressing the lactate dehydrogenase gene so as to shift the glycolytic flux towards the production of lactic acid.

25 FR-A-2 692 591 (Institut Nationale la Recherche Agronomique) discloses yeast strains, particularly Saccharomyces strains, containing at least one copy of a gene coding for a lactate dehydrogenase from a lactic bacterium, said gene being under the control of sequences  
30 regulating its expression in yeasts.

Said strains may give both the alcoholic and the

lactic fermentation and this so called "intermediate" or "balanced" fermentation could be exploited in areas such as brewing, enology, and baking.

Porro et al., (Biotechnol. Prog. 11, 294-298, 1995) have also reported the transformation of S. cerevisiae with a gene coding for bovine lactate dehydrogenase.

However, because of the high production of ethanol, the yield in the production of lactic acid for both the processes described was not considered to be competitive with that obtainable by the use of lactic bacteria.

In the past decade, "non conventional yeasts" other than S. cerevisiae have gained considerable industrial interest as host for the expression of heterologous proteins. Examples are the methanol-utilising yeasts such as Hansenula polymorpha and Pichia pastoris, the lactose-utilizing yeasts such as Kluyveromyces lactis. In addition to enabling the use of a wider range of substrates as carbon and energy sources, other arguments have been put forward to the industrial use of "non conventional yeasts". Generally speaking, biomass and product-yield are less affected, in some of these yeasts, by extreme conditions of the cellular environment. High-sugar-tolerant (i.e., 50-80% w/v glucose medium; Torulaspora -syn. Zygosaccharomyces delbrueckii, Zygosaccharomyces rouxii and Zygosaccharomyces bailii; Ok T and Hashinaga F., Journal of General & Applied Microbiology 43(1): 39-47, 1997) and acid- and lactic-tolerant (Zygosaccharomyces rouxii and Zygosaccharomyces bailii; Houtsma PC, et al., Journal of Food Protection 59(12), 1300-1304, 1996.) "non conventional yeasts" are available. As already underlined the cost of down stream

processing could be strongly reduced if the fermentation process is carried out under one or more of the above mentioned "extreme conditions".

Summary of the invention

5 According to a first embodiment, this invention provides yeast strains lacking ethanol production ability or having a reduced ethanol production ability and transformed with at least one copy of a gene coding for lactic dehydrogenase (LDH) functionally linked to  
10 promoter sequences allowing the expression of said gene in yeasts.

More particularly, this invention provides yeast strains having a reduced pyruvate dehydrogenase activity and a reduced pyruvate decarboxylase activity and  
15 transformed with at least one copy of a gene coding for lactic dehydrogenase (LDH) functionally linked to promoter sequences allowing the expression of said gene in yeasts.

According to another embodiment, this invention  
20 provides yeast strains of Kluyveromyces, Torulaspora and Zygosaccharomyces species, transformed with at least one copy of a gene coding for lactic dehydrogenase (LDH) functionally linked to promoter sequences allowing the expression of the gene in said yeasts.

25 According to a further embodiment, the invention also provides yeast cells transformed with a heterologous LDH gene and overexpressing a lactate transporter.

Other embodiments are the expression vectors comprising a DNA sequence coding for a lactic  
30 dehydrogenase functionally linked to a yeast promoter sequence and a process for the preparation of DL-, D- or



L-lactic acid by culturing the above described metabolically engineered yeast strains in a fermentation medium containing a carbon source and recovering lactic acid from the fermentation medium.

5 Furthermore, the invention provides processes for improving the productivity (g/l/hr), production (g/l) and yield (g/g) on the carbon source of lactic acid by culturing said yeast strains in a manipulated fermentation medium and recovering lactic acid from the  
10 fermentation medium.

Description of the invention

It has been found that production of lactic acid can be obtained by metabolically modified yeasts belonging to the genera Kluyveromyces, Saccharomyces, Torulaspora and  
15 Zygosaccharomyces.

More particularly, it has been found that very high yields in the production of lactic acid are obtained by engineered yeast strains so as to replace at least the ethanolic fermentation by lactic fermentation.

20 Even higher yields (>80% g/g) in the production of lactic acid may be obtained by engineered yeast strains so as to replace both the ethanolic fermentation and the use of pyruvate by the mitochondria by lactic fermentation.

25 To this purpose, the invention also provides transformed yeast cells having an increased LDH activity, for instance as a consequence of an increased LDH copy number per cell or of the use of stronger promoters controlling LDH expression.

30 An increased LDH copy number per cell means at least one copy of a nucleic acid sequence encoding for lactic

dehydrogenase protein, preferably at least two copies, more preferably four copies or, even more preferably, at least 10-50 copies of said nucleic acid sequence.

In order to have the highest production of lactic acid, yeast cells transformed according to the invention preferably overexpress a lactate transporter. This can be obtained by transforming yeast cells with one or more copies of a gene required for lactate transport.

The strains according to the invention can be obtained by several methods, for instance by genetic engineering techniques aiming at the expression of a lactate dehydrogenase activity, and by inactivating or suppressing enzymatic activities involved in the production of ethanol, e.g. pyruvate decarboxylase and alcohol dehydrogenase activities, and by inactivating or suppressing enzymatic activities involved in the utilisation of pyruvate by the mitochondria.

Since pyruvate decarboxylase catalyses the first step in the alcohol pathway, yeast strains without or having a substantially reduced pyruvate decarboxylase (PDC) activity and expressing a heterologous lactate dehydrogenase gene are preferred.

Further, since pyruvate dehydrogenase catalyzes the first step in the utilization of pyruvate by the mitochondria, yeast strains having no or a substantially reduced pyruvate dehydrogenase (PDH) activity and expressing a heterologous lactate dehydrogenase gene are also preferred.

Since lactate is excreted in the medium via a lactate transporter, cells producing lactic acid and overexpressing the lactate transporter are also

preferred.

The expression of a LDH gene in yeast strains allows the production of lactic acid at acid pH values so that the free acid is directly obtained and the cumbersome conversion and recovery of lactate salts are minimized. In this invention, the pH of the fermentation medium may initially be higher than 4.5, but will decrease to a pH of 4.5 or less, preferably to a pH of 3 or less at the termination of the fermentation.

Any kind of yeast strain may be used according to the invention, but Kluyveromyces, Saccharomyces, Torulaspora and Zygosaccharomyces species are preferred because these strains can grow and/or metabolize at very low pH, especially in the range of pH 4.5 or less; genetic engineering methods for these strains are well-developed; and these strains are widely accepted for use in food-related applications.

Good yields of lactic acid can moreover be obtained by Kluyveromyces, Torulaspora and Zygosaccharomyces strains transformed with a gene coding for lactic dehydrogenase having a "wild-type" pyruvate decarboxylase and/or a pyruvate dehydrogenase activity.

The term "reduced pyruvate decarboxylase activity" means either a decreased concentration of enzyme in the cell or reduced or no specific catalytic activity of the enzyme.

The term "reduced pyruvate dehydrogenase activity" means either a decreased concentration of enzyme in the cell or reduced or no specific catalytic activity of the enzyme.

According to the invention, it is preferred the use

of strains wherein the ethanol production is or approaches zero but a reduced production for instance at least 60% lower, preferably at least 80% lower and even more preferably at least 90% lower than the normal of wild-type strains is acceptable.

According to the invention, it is preferred the use of strains wherein the pyruvate decarboxylase and/or pyruvate dehydrogenase activities are or approach zero but a reduced activity for instance at least 60% lower, preferably at least 80% lower and even more preferably at least 90% lower than the normal of wild-type strains is acceptable.

An example of K. lactis having no PDC activity has been disclosed in Mol. Microbiol. 19 (1), 27-36, 1996.

Examples of Saccharomyces strains having a reduced PDC activity are available from ATCC under Acc.No. 200027 and 200028. A further example of a Saccharomyces strain having a reduced PDC activity as a consequence of the deletion of the regulatory PDC2 gene has been described in Hohmann S (1993)(*Mol Gen Genet* 241:657-666).

An example of a Saccharomyces strain having no PDC activity has been described in Flikweert M.T. et al. (*Yeast*, 12:247-257, 1996). In S. cerevisiae reduction of the PDC activity can be obtained either by deletion of the structural genes (PDC1, PDC5, PDC6) or deletion of the regulatory gene (PDC2).

An example of Kluyveromyces strain having no PDH activity has been described in Zeeman et al. (Genes involved in pyruvate metabolism in *K. lactis*; *Yeast*, vol

13 Special Issue April 1997, Eighteenth International  
Conference on Yeast Genetics and Molecular Biology,  
p143).

5 An example of Saccharomyces strain having no PDH  
activity has been described in Pronk JT. et al.  
(Microbiology. 140 (Pt 3):601-10, 1994).

PDC genes are highly conserved among the different  
yeast genera (Bianchi et al., Molecular Microbiology,  
19(1):27-36, 1996; Lu P. et al., Applied & Environmental  
10 Microbiology, 64(1):94-7, 1998). Therefore it can be  
easily anticipated that following classical molecular  
approaches, as reported by Lu P. et al. (supra), it is  
possible to identify, to clone and to disrupt the gene(s)  
required for a pyruvate decarboxylase activity from both  
15 Torulaspora and Zygosaccharomyces yeast species. Further,  
it can be also anticipated that following the same  
classical approaches, as reported by Neveling U. et al.  
(1998, Journal of Bacteriology, 180(6):1540-8, 1998), it  
is possible to isolate, to clone and to disrupt the  
20 gene(s) required for the PDH activity in both Torulaspora  
and Zygosaccharomyces yeast species.

The pyruvate decarboxylase activity can be measured  
by known methods, e.g. Ulbrich J., Methods in Enzymology,  
Vol. 18, p. 109-115, 1970, Academic Press, New York.

25 The pyruvate dehydrogenase activity can be measured  
by known methods, e.g. according to Neveling U. et al.  
(supra).

Suitable strains can be obtained by selecting  
mutations and/or engineering of wild-type or collection  
30 strains. Hundreds of mutants could be selected by "high  
throughput screen" approaches. The modulation of pyruvate

decarboxylase activity by using nutrients supporting different glycolytic flow rates (Biotechnol. Prog. 11, 294-298, 1995) did not prove to be satisfactory.

A preferred method for decreasing or destroying the pyruvate decarboxylase activity and/or pyruvate dehydrogenase activity in a yeast strain according to the invention consists in the deletion of the corresponding gene or genes.

These deletions can be carried out by known methods, such as that disclosed in Bianchi et al., (Molecular Microbiol. 19 (1), 27-36, 1996; Flikweert M.T. et al., Yeast, 12:247-257, 1996 and Pronk JT. et al., Microbiology. 140 (Pt 3):601-10, 1994), by deletion or insertion by means of selectable markers, for instance the URA3 marker, preferably the URA3 marker from Saccharomyces cerevisiae. Alternatively, deletions, point-mutations and/or frame-shift mutations can be introduced into the functional promoters and genes required for the PDC and/or PDH activities. These techniques are disclosed, for instance, in Nature, 305, 391-397, 1983. An addition method to reduce these activities could be the introduction of STOP codons in the genes sequences or expression of antisense mRNAs to inhibit translation of PDC and PDH mRNAs.

A Kluyveromyces lactis strain wherein the PDC gene has been replaced by the URA3 gene of S. cerevisiae has already been described in Molecular Microbiology 19(1), 27-36, 1996.

The gene coding for lactate dehydrogenase may be of any species (e.g. mammalian, such as bovine, or bacterial), and it may code for the L(+)-LDH or the D(-)-

LDH. Alternatively, both types of LDH genes may be expressed simultaneously. Further, any natural or synthetic variants of LDH DNA sequences, any DNA sequence with high identity to a wild-type LDH gene, any DNA  
5 sequence complementing the normal LDH activity may be used.

As transporter gene, for example the JEN1 gene, encoding for the lactate transporter of S. cerevisiae, can be used.

10 The transformation of the yeast strains can be carried out by means of either integrative or replicative vectors, linear or plasmidial.

The recombinant cells of the invention can be obtained by any method allowing a foreign DNA to be introduced  
15 into a cell (Spencer Jf, et al., Journal of Basic Microbiology 28(5): 321-333, 1988), for instance transformation, electroporation, conjugation, fusion of protoplasts or any other known technique. Concerning transformation, various protocols have been described: in  
20 particular, it can be carried out by treating the whole cells in the presence of lithium acetate and of polyethylene glycol according to Ito H. et al. (J. Bacteriol., 153:163, 1983), or in the presence of ethylene glycol and dimethyl sulphonyde according to  
25 Durrens P. et al. (Curr. Genet., 18:7, 1990). An alternative protocol has also been described in EP 361991. Electroporation can be carried out according to Becker D.M. and Guarente L. (Methods in Enzymology, 194:18, 1991).

30 The use of non-bacterial integrative vectors may be preferred when the yeast biomass is used, at the end of

the fermentation process, as stock fodder or for other breeding, agricultural or alimentary purposes.

In a particular embodiment of the invention, the recombinant DNA is part of an expression plasmid which  
5 can be of autonomous or integrative replication.

In particular, for both S. cerevisiae and K. lactis, autonomous replication vectors can be obtained by using autonomous replication sequences in the chosen host. Especially, in yeasts, they can be replication origins  
10 derived from plasmids (2 $\mu$ , pKD1, etc.) or even chromosomal sequence (ARS).

The integrative vectors can be obtained by using homologous DNA sequences in certain regions of the host genome, allowing, by homologous recombination,  
15 integration of the vector.

Genetic tools for gene expression are very well developed for S. cerevisiae and described in Romanos, M.A. et al. Yeast, 8:423, 1992. Genetic tools have been also developed to allow the use of the yeasts  
20 Kluyveromyces and Torulaspora species as host cells for production of recombinant proteins (Spencer Jf, et al., supra; Reiser J. et al., Advances in Biochemical Engineering-Biotechnology. 43, 75-102, 1990). Some examples of vectors autonomously replicating in K. lactis  
25 are reported, either based on the linear plasmid pKG1 of K. lactis (de Lovencourt L. et al. J. Bacteriol., 154:737, 1982), or containing a chromosomal sequence of K. lactis itself (KARS), conferring to the vector the ability of self replication and correct segregation (Das  
30 S., Hollenberg C.P., Curr. Genet., 6:123, 1982). Moreover, the recognition of a 2 $\mu$ -like plasmid native to



K. drosophilum (plasmid pKD1- US 5 166 070) has allowed a very efficient host/vector system for the production of recombinant proteins to be established (EP-A- 361 991). Recombinant pKD1-based vectors contain the entire  
5 original sequence, fused to appropriate yeast and bacterial markers. Alternatively, it is possible to combine part of pKD1, with common S. cerevisiae expression vectors (Romanos M.A. et al. Yeast, 8:423, 1992)(Chen et al., Curr. Genet. 16: 95, 1989).

10 It is known that the 2 $\mu$  plasmid from S. cerevisiae replicates and is stably maintained in Torulaspora. In this yeast the expression of heterologous protein(s) has been obtained by a co-transformation procedure, i.e. the simultaneous presence of an expression vector for S.  
15 cerevisiae and of the whole 2 $\mu$  plasmid. (Compagno C. et al., Mol. Microb., 3:1003-1010, 1989). As a result of inter and intra molecular recombinations, it is possible to isolate a hybrid plasmid, bearing the complete 2 $\mu$  sequence and the heterologous gene; such a plasmid is in  
20 principle able to directly transform Torulospora.

Moreover, an episomal plasmid based on S. cerevisiae ARS1 sequence has also been described, but the stability of this plasmid is very low, Compagno et al. (supra).

25 Recently, an endogenous, 2 $\mu$ -like plasmid named pTD1 has been isolated in Torulaspora (Blaisonneau J. et al., Plasmid, 38:202-209, 1997); the genetic tools currently available for S. cerevisiae can be transferred to the new plasmid, thus obtaining expression vectors dedicated to Torulaspora yeast species.

30 Genetic markers for Torulaspora yeast comprise, for instance, URA3 (Watanabe Y. et al., FEMS Microb. Letters,

145:415-420, 1996), G418 resistance (Compagno C. et al., Mol. Microb., 3:1003-1010, 1989), and cicloheximide resistance (Nakata K. et Okamura K., Biosc.Biotechnol.Biochem., 60:1686-1689, 1996).

5        2 $\mu$ -like plasmids from Zygosaccharomyces species are known and have been isolated in Z. rouxii (pSR1), in Z. bisporus (pSB3), in Z. fermentati (pSM1) and in Z. bailii (pSB2) (Spencer JF. et al., supra).

Plasmid pSR1 is the best known: it is replicated in  
10    S. cerevisiae, but 2 $\mu$  ARS are not recognized in Z. rouxii (Araki H. and Hoshima Y., J.Mol. Biol., 207:757-769, 1989).

Episomal vectors based on S. cerevisiae ARS1 are described for Z. rouxii (Araki et al., Mol Gen.Genet.,  
15    238:120-128, 1993).

A selective marker for Zygosaccharomyces is the gene APT1 allowing growth in media containing G418 (Ogawa et al., Agric.Biol.Chem., 54:2521-2529, 1990).

Any yeast promoter, either inducible or constitutive,  
20    may be used according to the invention. To date, promoters used for the expression of proteins in S. cerevisiae are well described by Romanos et al. (supra). Promoters commonly used in foreign protein expression in K. lactis are S. cerevisiae PGK and PHO5 (Romanos et al.,  
25    supra), or homologous promoters, such as LAC4 (van den Berg J. A. et al., BioTechnology, 8:135, 1990) and K1PDC (US 5 631 143). The promoter of pyruvate decarboxylase gene of K. lactis (K1PDC) is particularly preferred.

Vectors for the expression of heterologous genes  
30    which are particularly efficient for the transformation of Kluyveromyces lactis strains are disclosed in US 5 166

070, which is herein incorporated by reference.

Pyruvate decarboxylase gene promoters, preferably from Kluyveromyces species and even more preferably from Kluyveromyces lactis, disclosed in Molecular Microbiol. 19(1), 27-36, 1996, are particularly preferred. Triose phosphate isomerase and alcohol dehydrogenase promoters, preferably from Saccharomyces species and even more preferably from Saccharomyces cerevisiae, are also preferred (Romanos et al, supra).

For the production of lactic acid, the yeast strains of the invention are cultured in a medium containing a carbon source and other essential nutrients, and the lactic acid is recovered at a pH of 7 or less, preferably at a pH of 4.5 or less, and even more preferably at a pH of 3 or less. Since the pH of the culture medium is reduced, a lower amount of neutralizing agent is necessary. The formation of lactate salt is correspondingly reduced and proportionally less regeneration of free acid is required in order to recovery lactic acid. The recovery process may employ any of the known methods (T.B. Vickroy, Volume 3, Chapter 38 of "Comprehensive Biotechnology," (editor: M. Moo-Young), Pergamon, Oxford, 1985.)(R. Datta et al., FEMS Microbiology Reviews 16, 221-231,1995). Typically, the microorganisms are removed by filtration or centrifugation prior to lactic acid recovery. Known methods for lactic acid recovery include, for instance, the extraction of lactic acid into an immiscible solvent phase or the distillation of lactic acid or an ester thereof. Higher yields with respect to the carbon source (g of lactic acid/g of glucose consumed) and higher

productivities (g of lactic acid/l/h) are obtained by growing yeast strains, particularly Saccharomyces strains, in media lacking  $Mg^{++}$  and  $Zn^{++}$  ions or having a reduced availability of said ions. Preferably, culture  
5 media will contain less than 5 mM of  $Mg^{++}$ , and/or less than 0.02 mM of  $Zn^{++}$ .

The present invention offers the following advantages in the production of lactic acid:

1. When the fermentation is carried out at pH 4.5 or  
10 less, there is less danger of contamination by foreign microorganisms, as compared with the conventional process. Further, the fermentation facility can be simplified and the fermentation control can be facilitated.
- 15 2. Since less neutralizing agent is added to the culture medium for neutralization, there is correspondingly less need to use mineral acids or other regenerating agents for conversion of the lactate salt to free lactic acid. Therefore, the production cost can be  
20 reduced.
3. Since less neutralizing agent is added to the culture medium, the viscosity of the culture broth is reduced. Consequently, the broth is easier to process.
- 25 4. The cells separated in accordance with the present invention can be utilized again as seed microorganisms for a fresh lactic acid fermentation.
5. The cells can be continuously separated and recovered during the lactic acid fermentation, in accordance  
30 with the present invention, and hence, the fermentation can be carried out continuously.

6. Since the recombinant yeast strains lack ethanol production ability and pyruvate dehydrogenase activity or have both a reduced ethanol production and a reduced pyruvate dehydrogenase activity, the production of lactic acid can be carried out with higher yield in comparison to yeast strains having both a wild-type ability to produce ethanol and a wild-type ability for the utilization of pyruvate by the mitochondria.
7. The production of lactic acid by metabolically engineered non-conventional yeasts belonging to the Kluyveromyces, Torulaspora and Zygosaccharomyces species can be obtained from non conventional carbon sources (i.e., galactose-lactose-sucrose-raffinose-maltose-cellobiose-arabinose-xylose, to give some examples), growing the cells in high-sugar medium and growing the cells in presence of high concentration of lactic acid.

#### Brief description of the Figures

- Fig.1. Cloning of the lactate dehydrogenase gene shifts the glycolytic flux towards the production of lactic acid.

Key enzymatic reactions at the pyruvate branch-point are catalysed by the following enzymes: (1): pyruvate decarboxylase; (2): alcohol dehydrogenase; (3): acetaldehyde dehydrogenase; (4): acetyl-CoA synthetase; (5): acetyl-CoA shuttle from the cytosol to mitochondria; (6): acetyl-CoA shuttle from mitochondria to the cytosol; (7): heterologous lactate dehydrogenase. (8): pyruvate dehydrogenase. Enzymatic reactions involved in anaplerotic syntheses have been omitted.

Fig. 2. Diagram of the plasmid pVC1.

Fig. 3A., 3B. Diagram of the plasmid pKSMD8/7 and pKSEXH/16, respectively.

Fig. 4. Diagram of the plasmid pEPL2.

5 Fig. 5. Diagram of the plasmid pLC5.

Fig. 6. Diagram of the plasmid pLAT-ADH.

Fig. 7A. L(+)-Lactic acid production from the transformed Kluyveromyces lactis PM6-7a[pEPL2] during growth on Glu-YNB based media. The residual glucose  
10 concentration at T=49 was not detectable. Production of D(-)-lactic acid was not detectable too. The LDH specific activity was higher than 3 U/mg of total cell protein along all the experiment.

Similar results have been obtained using the  
15 bacterial L. casei LDH (data not shown).

(Δ) cells/ml; (-) pH value; (O) Ethanol production, g/l  
(■) L(+)-Lactic acid production, g/l

Fig. 7B. L(+)-Lactic acid production from the transformed Kluyveromyces lactis PM6-7a[pEPL2] during  
20 growth on Glu-YNB based media. Medium was buffered at time T=0 (pH=5.6) using 200mM phosphate buffer. In this text batch, the pH value decreases much later than during the text batch shown in figure 7A. The residual glucose concentration at T=49 was not detectable. The LDH  
25 specific activity was higher than 3 U/mg of total cell protein along all the experiment.

Similar results have been obtained using the bacterial L. casei LDH (data not shown).

(Δ) cells/ml; (-) pH value; (O) Ethanol production, g/l  
30 (■) L(+)-Lactic acid production, g/l

Fig. 8A. L(+)-Lactic acid production from the

transformed Kluyveromyces lactis PM1/C1[pEPL2] during growth on Glu-YNB based media. The residual glucose concentration at T=60 was 12,01 g/l. Longer incubation times did not yield higher productions of both biomass and L(+)-Lactic acid. The LDH specific activity was higher than 3 U/mg of total cell protein along all the experiment.

Similar results have been obtained using the bacterial L. casei LDH (data not shown).

10 (▲) cells/ml; (-) pH value; (O) Ethanol production, g/l  
(■) L(+)-Lactic acid production, g/l

Fig.8B. L(+)-Lactic acid production from the transformed Kluyveromyces lactis PM1/C1[pEPL2] during growth on Glu-YNB based media. Medium was buffered at time T=0 (pH=5.6) using 200mM phosphate buffer In this text batch, the pH value decreases much later than during the text batch shown in figure 8A. The residual glucose concentration at T=87 was zero. The LDH specific activity was higher than 3 U/mg of total cell protein along all the experiment.

20 (▲) cells/ml; (-) pH value; (O) Ethanol production, g/l  
(■) L(+)-Lactic acid production, g/l

Similar results have been obtained using the bacterial L. casei LDH (data not shown).

25 Fig.9A. L(+)-Lactic acid production from the transformed Kluyveromyces BM3-12D[pLAZ10] cells in stirred tank bioreactor (see also text)

(▲) cells/ml; (O) Glucose concentration, g/l  
(■) L(+)-Lactic acid production, g/l

30 Fig.9B. L(+)-Lactic acid yield from the transformed Kluyveromyces BM3-12D[pLAZ10] cells in

stirred tank bioreactor.

Glucose Vs lactic acid production. The yield (g/g) is 85.46 %.

Fig.10. L(+)-Lactic acid production from the transformed Torulaspora (syn. Zygosaccharomyces) delbrueckii CBS817[pLAT-ADH] during growth on Glu-YNB based media. The residual glucose concentration at T=130 was 3 g/l. Longer incubation times did not yield higher productions of both biomass and L(+)-Lactic acid. The LDH specific activity was higher than 0.5 U/mg of total cell protein along all the experiment.

(▲) cells/ml; (-) pH value; (○) Ethanol production, g/l  
(■) L(+)-Lactic acid production, g/l

Fig.11. L(+)-Lactic acid production from the transformed Zygosaccharomyces bailii ATCC60463[pLAT-ADH] during growth on Glu-YNB based media. The residual glucose concentration at T=60 was 8 g/l. Longer incubation times did not yield higher productions of both biomass and L(+)-Lactic acid. The LDH specific activity was higher than 0.5 U/mg of total cell protein along all the experiment. Similar results were obtained using a different strain (ATCC36947, data not shown)

(▲) cells/ml; (-) pH value; (○) Ethanol production, g/l  
(■) L(+)-Lactic acid production, g/l

## Detailed description of the invention

### Definitions

The following definitions are provided in order to aid those skilled in the art in understanding the detailed description of the present invention.

"Amplification" refers to increasing the number of copies of a desired nucleic acid molecule.



## 21

"Codon" refers to a sequence of three nucleotides that specify a particular amino acid.

"Deletion" refers to a mutation removing one or more nucleotides from a nucleic acid sequence.

5        "DNA ligase" refers to an enzyme that covalently joins two pieces of double-stranded DNA.

      "Electroporation" refers to a method of introducing foreign DNA into cells that uses a brief, high voltage dc charge to permeabilize the host cells, causing them to  
10      take up extra-chromosomal DNA.

      The term "endogenous" refers to materials originating from within the organism or cell.

      "Endonuclease" refers to an enzyme that hydrolyzes double stranded DNA at internal locations.

15        The term "expression" refers to the transcription of a gene to produce the corresponding mRNA and translation of this mRNA to produce the corresponding gene product, i.e., a peptide, polypeptide, or protein.

      The term "expression of antisense RNA" refers to the  
20      transcription of a DNA to produce a first RNA molecule capable of hybridizing to a second RNA molecule encoding a gene product, e.g. a protein. Formation of the RNA-RNA hybrid inhibits translation of the second RNA molecule to produce the gene product.

25        The phrase "functionally linked" refers to a promoter or promoter region and a coding or structural sequence in such an orientation and distance that transcription of the coding or structural sequence may be directed by the promoter or promoter region.

30        The term "gene" refers to chromosomal DNA, plasmid DNA, cDNA, synthetic DNA, or other DNA that encodes a

peptide, polypeptide, protein, or RNA molecule, and regions flanking the coding sequence involved in the regulation of expression.

The term "genome" encompasses both the chromosome and  
5 plasmids within a host cell. Encoding DNAs of the present invention introduced into host cells can therefore be either chromosomally-integrated or plasmid-localized.

"Heterologous DNA" refers to DNA from a source  
10 different than that of the recipient cell.

"Homologous DNA" refers to DNA from the same source as that of the recipient cell.

"Hybridization" refers to the ability of a strand of nucleic acid to join with a complementary strand via base  
15 pairing. Hybridization occurs when complementary sequences in the two nucleic acid strands bind to one another.

"Lactate dehydrogenase" (LDH) refers to a protein that catalyzes the conversion of pyruvate and NADH to lactic  
20 acid and NAD<sup>+</sup>. L(+)-LDH produces L(+)-lactic acid; D(-)-LDH produces D(-)-lactic acid.

The term "lactate transporter" refers to a protein that allows the transport of lactate from inside to outside the cell.

25 "Mutation" refers to any change or alteration in a nucleic acid sequence. Several types exist, including point, frame shift, and splicing. Mutation may be performed specifically (e.g. site directed mutagenesis) or randomly (e.g. via chemical agents, passage through  
30 repair minus bacterial strains).

Nucleic acid codes: A = adenosine; C = cytosine; G =

## 23

guanosine; T = thymidine; N = equimolar A, C, G, and T; I = deoxyinosine; K = equimolar G and T; R = equimolar A and G; S = equimolar C and G; W = equimolar A and T; Y = equimolar C and T.

5 "Open reading frame (ORF)" refers to a region of DNA or RNA encoding a peptide, polypeptide, or protein.

"Pyruvate decarboxylase" (PDC) refers to a protein which catalyzes the conversion of pyruvate to acetaldehyde.

10 "Pyruvate dehydrogenase" (PDH) refers to a protein complex which catalyzes the conversion of pyruvate to acetyl-CoA.

"Plasmid" refers to a circular, extrachromosomal, self-replicating piece of DNA.

15 "Point mutation" refers to an alteration of a single nucleotide in a nucleic acid sequence.

"Polymerase chain reaction (PCR)" refers to an enzymatic technique to create multiple copies of one sequence of nucleic acid. Copies of DNA sequence are prepared by shuttling a DNA polymerase between two  
20 amplimers. The basis of this amplification method is multiple cycles of temperature changes to denature, then re-anneal amplimers, followed by extension to synthesize new DNA strands in the region located between the  
25 flanking amplimers.

The term "promoter" or "promoter region" refers to a DNA sequence, that includes elements controlling the production of messenger RNA (mRNA) by providing the recognition site for RNA polymerase and/or other factors  
30 necessary for start of transcription at the correct site.

A "recombinant cell" or "transformed cell" is a cell

whose DNA has been altered by the introduction of an exogenous nucleic acid molecule into that cell.

The term "recombinant DNA construct" or "recombinant vector" refers to any agent such as a plasmid, cosmid, virus, autonomously replicating sequence, phage, or linear or circular single-stranded or double-stranded DNA or RNA nucleotide sequence, derived from any source, capable of genomic integration or autonomous replication, comprising a DNA molecule in which one or more DNA sequences have been linked in a functionally operative manner. Such recombinant DNA constructs or vectors are capable of introducing a 5' regulatory sequence or promoter region and a DNA sequence for a selected gene product into a cell in such a manner that the DNA sequence is transcribed into a functional mRNA which is translated and therefore expressed. Recombinant DNA constructs or recombinant vectors may alternatively be constructed to be capable of expressing antisense RNAs, in order to inhibit translation of a specific RNA of interest.

"Reduced (enzymatic) activity" refers to lower measured enzymatic activity isolated from a transformed or mutagenized strain as compared to the measured enzymatic activity isolated from a wild type strain of the same species. Reduced enzymatic activity may be the result of lowered concentrations of the enzyme, lowered specific activity of the enzyme, or a combination thereof.

"Repair minus" or "repair deficient" strains refer to organisms having reduced or eliminated DNA repair pathways. Such strains demonstrate increased mutation

rates as compared to the rates of wild type strains of the same species. Propagation of a nucleic acid sequence through a repair minus strain results in the incorporation of random mutations throughout the nucleic acid sequence.

"Restriction enzyme" refers to an enzyme that recognizes a specific palindromic sequence of nucleotides in double stranded DNA and cleaves both strands; also called a restriction endonuclease. Cleavage typically occurs within the restriction site.

"Selectable marker" refers to a nucleic acid sequence whose expression confers a phenotype facilitating identification of cells containing the nucleic acid sequence. Selectable markers include those which confer resistance to toxic chemicals (e.g. ampicillin resistance, kanamycin resistance), complement a nutritional deficiency (e.g. uracil, histidine, leucine), or impart a visually distinguishing characteristic (e.g. color changes, fluorescence).

"Transcription" refers to the process of producing an RNA copy from a DNA template.

"Transformation" refers to a process of introducing an exogenous nucleic acid sequence (e.g., a vector, plasmid, recombinant nucleic acid molecule) into a cell in which that exogenous nucleic acid is incorporated into a chromosome or is capable of autonomous replication.

"Translation" refers to the production of protein from messenger RNA.

The term "yield" refers to the amount of lactic acid produced (gr/l) divided by the amount of glucose consumed (gr/l).

"Unit" of enzyme refers to the enzymatic activity and indicates the amount of micromoles of substrate converted per mg of total cell proteins per minute.

"Vector" refers to a plasmid, cosmid, bacteriophage, or virus that carries nucleic acid sequences into a host organism.

Site-directed mutagenesis of the bovine lactate dehydrogenase gene (LDH-A)

In order to isolate from the full length cDNA the coding sequence of the bovine enzyme LDH-A (EC 1.1.1.27), a classical site directed mutagenesis, (J. Biol. Chem. 253:6551, 1978, Meth. Enzymol. 154:329, 1987), was performed. Oligonucleotides-driven site-specific mutagenesis is based on the *in vitro* hybridization of a single strand DNA fragment with a synthetic oligonucleotide, which is complementary to the DNA fragment except for a central mismatching region in correspondence of the DNA sequence that must to be mutagenized.

In order to introduce a Xba I restriction enzyme site 11 bp before the ATG codon, the 1743 bp bovine LDH cDNA was cloned from the plasmid pLDH12 (Ishiguro et al., Gene, 91 281-285, 1991) by digestion with Eco RI and Hind III restriction enzymes (New England Biolabs, Beverly, MA). The isolated DNA fragment was then inserted in the pALTER-1 (Promega, cat # 96210; lot # 48645, 1996) expression vector.

Such vector contains M13 and R408 bacteriophages origin of replication and two genes for antibiotic resistance. One of these genes, for tetracycline resistance, is functional. The other (i.e., ampicillin

resistance) has been inactivated. An oligonucleotide is provided which restores ampicillin resistance to the mutant strand during mutagenesis reaction (oligoAMP; Promega, Madison, WI Tab. 1). This oligonucleotide is  
 5 annealed to the single-stranded DNA (ssDNA) template. At the same time the mutagenic oligonucleotide (oligoLDH, Madison WI) has been annealed as well. Following DNA synthesis and ligation, the DNA is transformed into a repair minus strain of *E. coli* (BMH 71-18 mutS; kit  
 10 Promega). Selection was performed on LB+ampicillin (Molecular Cloning a laboratory manual, edited by Sambrook et al., Cold Spring Harbor Laboratory Press). A second round of transformation in JM 109 (kit Promega) *E. coli* strain ensured proper segregation of mutant and wild  
 15 type plasmids.

---

OLIGONUCLEOTIDES	SEQUENCE
OligoAMP	5'-GTTGCCATTGCTGCAGGCATCGTGGTG-3'
(Sequence Id. No. 1)	
20 OligoLDH	5'-CCTTTAGGGTCTAGATCCAAGATGGCAAC-3'
(Sequence Id. No. 2)	

---

Table 1: Nucleotide sequence of the synthetic oligonucleotides used for the site-directed mutagenesis.  
 25 The underlined sequence in the oligoLDH show the Xba I restriction site introduced by mutagenesis.

Further details of the technique and material used (with the exception of the oligoLDH) can be found in the kit datasheet.

30 The plasmid obtained, containing the mutated cDNA for the bovine LDH, was denominated pVC1 (Fig. 2).

PCR mutagenesis of the bacterial lactate dehydrogenase gene (LDH) from Lactobacillus casei, Bacillus megaterium and Bacillus stearothermophilus.

The original starting codon (GTG) of the  
5 Lactobacillus casei LDH gene (GTG) (the LDH sequence is  
available at the accession n. M76708 of the GenBank  
Sequence Database provided by the National Center of  
Biotechnology -NCBI- Web site:  
<http://www.ncbi.nlm.nih.gov/>) is not correctly recognised  
10 by S. cerevisiae. We obtained plasmid pST2 and LDH  
sequence from Hutkins Robert, University of Nebraska,  
USA). pST2 is based on pUC19 vector (Boehringer Mannheim  
GmbH, Mannheim, Germany, cat.885827) and contains a  
BamHI-SphI LDH-cDNA fragment amplified from the L. casei  
15 686 (Culture collection of the University of Nebraska).

In order to obtain a coding sequence starting with the  
usual eukaryotic first codon (i.e. ATG), the LDH sequence  
has been mutagenised via PCR.

The introduction of a Nco I restriction enzyme site at  
20 position 163 of the LDH sequence (accession n. M76708 of  
the GenBank Sequence Database, supra), allows the  
concomitant change of the original GTG codon into ATG.  
PCR reaction (Mastercycler 5330, Eppendorf, Hamburg,  
Germany) was performed starting from the plasmid pLC1,  
25 based on pGEM7Z f(+) (Promega corporation, Madison WI,  
USA, cat.P2251) vector, and containing the L.casei's gene  
(fragment BamHI-SphI excided from pST2). The sequences of  
the oligonucleotides used as primers of the reaction are  
reported in Table 2.

30 Amplification cycles : 94°; 1' (denaturing step)  
94° 30" (denaturing step)



29

56° 30"      4 times      (primer annealing step)  
 68° 3'      (extension step)  
 94° 30"      (denaturing step)  
 60° 30"      23 times      (primer annealing step)  
 5    68° 3'      (extension step)  
      68° 3'      (final extension step)

At the end of the reaction, a single band, corresponding to the amplified and mutated gene, was isolated. The DNA fragment was then inserted at the EcoRV  
 10 site of pMOSBlue (Amersham Life Science, Buckinghamshire, England; cod. RPN5110) cloning vector with a blunt-end ligation, giving rise to pLC3 plasmid.

Any other mutagenesis's protocol can be analogously used.

15      Table 2

OLIGONUCLEOTIDES	SEQUENCE
OligoATG (Sequence Id. No. 3)	5'- <u>CCATGG</u> CAAGTATTACGGATAAGGATC-3'
OligoANTISENSE (Sequence Id. No. 4)	5'-CTATCACTGCAGGGTTTCGATGTC-3'

Table 2: Nucleotide sequence of the synthetic oligonucleotides used for the PCR amplification. The underlined sequences in the oligoATG shows the NcoI  
 20 restriction site introduced by mutagenesis, and the resulting ATG starting codon obtained.

Following a classical PCR approach we also cloned the L(+) LDH genes from the bacteria Bacillus megaterium and Bacillus stearothermophilus (Biol. Chem. Hoppe-Seyler,  
 25 1987, 368: 1391)(Biol. Chem. Hoppe-Seyler, 1987, 368:

1167)(the DNA sequence is also available at the accession  
n. M22305 and M19396 of the Genbank Sequence Database  
provided by the National Center of Biotechnology -NCBI-  
Web site: <http://www.ncbi.nlm.nih.gov/>) in expression  
5 vectors for yeasts S. cerevisiae (i.e., pBME2 and pBST2,  
respectively- see below).

Construction of the pEPL2 replicative vector  
containing the K1PDCA promoter and the bovine LDH cDNA.

The K1PDCA promoter and the coding sequence were  
10 subcloned as a 4 Kbp HindIII fragment from a K. lactis  
genomic library clone complementing the rag 6 mutation of  
K. lactis (Bianchi et al., Mol. Microbiol., 19: 27-36,  
1996). The promoter region was subcloned into Sal I and  
Xba I sites of the vector pBleuscript II KS (Stratagene,  
15 LaJolla, Ca # 212205) with T4 DNA ligase using molecular  
cloning standard procedure (Sambrook et al., Molecular  
Cloning, supra). The bovine LDH sequence, isolated as a  
Xba I-Hind III fragment of 1675 bp from the pVC1 vector,  
was cloned in the corresponding cloning sites of the  
20 vector pBleuscript II KS. GM82 *E. coli* strain (*dam*<sup>-</sup>  
*dcm*<sup>-</sup>)(available from ATCC or CGSC collections) was  
transformed with the two new vectors, called respectively  
pKSMD8/7 and pKSEXH/16 (Fig 3A and 3B).

K1PDCA promoter and bovine LDH sequence, isolated as  
25 Sal I-Xba I fragments, respectively from pKSMD8/7 and  
pKSEXH/16, were ligated in vitro with T4 DNA ligase at  
room temperature in the presence of Sal I endonuclease in  
order to allow the ligation at Xba I ends. The ligation  
product was cloned in Sal I cloning site of pE1 vector  
30 (Bianchi M. et al., Curr. Genet. 12: 185-192, 1987; Chen  
X. J. et al., Curr. Genet. 16: 95-98, 1989 and US #

5166070). This plasmid is based on the YIp5 integrative plasmid containing the Saccharomyces cerevisiae genetic marker URA3 and on the pKD1 plasmid (US # 5166070), isolated from Kluyveromyces drosophilarum. The plasmid pE1 has a functional organization similar to the S. cerevisiae 2 $\mu$  DNA and is able to replicate in a stable way in Kluyveromyces lactis cells (Chen X. J. et al., supra). The URA3 marker on the plasmid allows the complementation of the K. lactis uraA1-1 mutation (de Louvencourt et al., J. Bacteriol. 154: 737-742 (1982)), and therefore growth of transformed cells in selective medium without uracil.

The vector obtained was called pEPL2 (Fig. 4) and used to transform E. coli DH5- $\alpha$  strain (Life Technologies Inc., Gaithersburg, MA).

Construction of the pEPL4 replicative vector containing the K1PDCA promoter and the bacterial LDH gene.

The bovine LDH gene described for the pEPL2 plasmid was substituted with the LDH DNA sequence from the bacterial Lactobacillus casei gene (see above), following classical molecular approaches described throughout the text, yielding the plasmid pEPL4. Transformed K. lactis yeast cells bearing the bovine or bacterial LDHs gave similar results.

Construction of the pLAZ10 replicative vector containing the K1PDCA promoter and the bovine LDH cDNA.

Vector pLAZ10 was obtained by cloning the *Sal*I fragment of pEPL2, bearing the *K1PDC1* promoter and the bovine *LDH* coding sequence, into the unique *Sal*I site of vector p3K31. Vector p3K31 is composed of the commercial

vector pUC19 and the G418 resistance cassette of vector pKan707 (Fleer et al. Bio/technology 9: 968-974, 1991) inserted in the unique *SphI* site of plasmid pKD1.

Construction of the pLC5, pLC7, pB1, pBM2, pBST2,

5 pLC5-KanMX and pJEN1 integrative vectors.

The L. casei LDH gene, was excised from pLC3 (described above) with a *NcoI*-*SalI* digestion, and ligated into pYX012 or pYX022 integrative vectors (R&D System Europe Ltd, Abingdon, England).

10 The two plasmids obtained, containing the mutated DNA for the bacterial LDH gene under the control of the TPI promoter, and carrying the auxotrophic markers URA3 or HIS3, were denominated respectively pLC5 (figure 5) and pLC7. For the construction of pB1, pBM2 and pBST2 we  
15 used an approach similar to that described for the construction of pLC5; however, we used the bovine LDH, the B. megaterium LDH and the B. stearothermophilus LDH (Biol. Chem. Hoppe-Seyler, 1987, 368: 1391)(Biol. Chem. Hoppe-Seyler, 1987, 368: 1167), respectively. Finally,  
20 plasmid pFA6a-KanMX (Wach et al, Yeast, 1994, 10:1793-1808) was digested with *SacI* and *SmaI* and the resulting fragment was ligated into pLC5 cut with the same enzymes yielding the plasmid pLC5-kanMX. On the plasmids, the LDH gene is under the control of the TPI promoter.

25 The DNA sequence of JEN1 (the DNA sequence is available at the accession n. U24155 of the Genbank Sequence Database provided by the National Center of Biotechnology -NCBI- Web site:  
<http://www.ncbi.nlm.nih.gov/>), encoding for the lactate  
30 transporter of S. cerevisiae (Davis E.S., Thesis, 1994-Laboratory of Eukaryotic Gene Expression, Advanced

Bioscience Laboratories) (Davis, E.S. et al., Proc. Natl. Acad. Sci. U.S.A. 89 (23), 11169, 1992)(Andre, B. Yeast (11), 1575, 1995), has been obtained from E.S. Davis (University of Maryland, USA). The JEN1 coding sequence  
5 has been amplified by classical PCR approach described throughout the text and cloned into the plasmid pYX022 (see above). On the integrative plasmid, JEN1 overexpression is under the control of the TPI promoter.

Construction of the pLAT-ADH replicative vector  
10 containing the ADH1 promoter and the bovine LDH cDNA.

First, the pLDH-Kan plasmid was constructed, cloning at EcoRV site of the pBluescript II KS (Promega corporation, Madison WI, USA, cat. 212208) cloning vector the *APT1* gene, conferring geneticin (G418) resistance,  
15 derived from a SmaI/EcoRV digestion of pFA6-KanMX4 vector (Wach et al. Yeast 10:1793-1808 (1994)).

Secondly, the coding region of bovine *LDH* gene was cloned under the control of *S. cerevisiae*'s ADH1 promoter and terminator sequences by subcloning a XbaI/HindIII  
20 fragment, from the previously described pVC1 plasmid into pVT102-U vector (Vernet et al. Gene 52:225-233 (1987)).

Finally, the whole expression cassette (ADH1 promoter - *LDH* gene - ADH1 terminator) was excised with a SphI digestion and ligated with pLDH-Kan, linearized with  
25 SphI, obtaining pLAT-ADH vector (Fig.6)

Isolation of the *K. lactis* PMI/C1 strain

Deletion of the *KLPDCA* gene in the PM6-7A yeast strain (MAT a, adeT-600, uraA1-1)(Wesolowski et al., Yeast 1992, 8: 711) yielded the strain PMI. Deletion has  
30 been carried out by insertion of the URA3 marker of *S. cerevisiae*. The strain PMI grows on glucose containing

media; PDC activity is not detectable and the strain does not produce ethanol (Bianchi M.M., et al., (1996), supra). It is important to underline that S. cerevisiae cells without any detectable PDC activity do not grow on  
5 glucose mineral media (Flikweert M.T. et al. Yeast, 12:247-257, 1996).

$1 \times 10^7$ – $3 \times 10^7$  cells from a stationary culture of PMI yeast cells were plated on synthetic medium containing 5-fluoroorotic acid. Growth of yeast cells in media  
10 containing 5-fluoroorotic acid allows the selection of cells impaired in uracile synthesis (McCusker and Davis, Yeast 7: 607-608 (1991)). After 5 days incubation at 28° C some ura- mutants were isolated. One of these mutants obtained, called PMI/C1, resulted mutated in the URA3  
15 gene previously introduced by integrative transformation, as it resulted from a complementation test by transformation with an URA3 gene-containing plasmid (Kep6 vector; Chen et al., J. Basic Microbiol. 28: 211-220 (1988)). The genotype of PMI/C1 is the following: MATa,  
20 adeT-600, uraA1-1, pdcA::ura3.

Isolation of the CENPK113APDC1APDC5APDC6 CENPK113APDC2 and GRF18UAPDC2 strain

The general strategy was to generate first single deletion mutants of each of the PDC genes (PDC1, PDC2,  
25 PDC5 and PDC6). The gene deletions were performed by integration of a loxP-Kan<sup>SRD</sup>-loxP cassette by homologous recombination at the locus of the corresponding PDC gene using the short flanking homology (SFH) PCR method described by Wach et al. (1994; Yeast 10, 1793-1808) and  
30 Güldener et al. (1996; Nucleic Acids Res. 24, 2519-2524). Subsequently the deletion cassette was removed by

expressing the cre-recombinase leading behind a single copy of the loxP site at the deletion locus. The *pdc1 pdc5 pdc6* triple deletion mutant was created by subsequently crossing the single haploid deletion strains.

The PCR reaction was carried out on a DNA-template containing the gene for the kanamycin resistance (open reading frame of the *E. coli* transposon Tn903) fused to control sequences (promotor/terminator) of a certain *Schwanniomyces occidentalis* gene (confidential). This selection cassette is flanked on both ends by a loxP sequence (loxP-Kan<sup>SRD</sup>-loxP) and was developed by SRD (Scientific Research and Development GmbH). The used primer to amplify the loxP-Kan<sup>SRD</sup>-loxP cassette are designed so that the DNA sequence of the sense primer is homologous to the 5'-end of the selection cassette sequence and so that the primer presents in addition at its 5'-end a region 40 nucleotides, which corresponds to the 5'-terminal sequence of the certain *Saccharomyces cerevisiae* PDC gene. The antisense primer is constructed in an analogous manner, it is complementary to the 3'-end of the selection cassette, wherein this primer contains at its 5'-end a region of also preferably 40 nucleotides, which corresponds to the 3'-terminal sequence of the certain *Saccharomyces cerevisiae* PDC gene.

The following table shows the primers used for gene deletion of the corresponding PDC genes by SFH PCR method. Sequences underlined are homologue to the corresponding PDC gene and sequences complementary to the loxP-Kan<sup>SRD</sup>-loxP cassette are in bold letters.

PDC1-S1	<u>TTC TAC TCA TAA CCT CAC GCA AAA TAA CAC</u> <u>AGT CAA ATC ACA GCT GAA GCT TCG TAC GC</u>
PDC1-S2	<u>AAT GCT TAT AAA ACT TTA ACT AAT AAT TAG</u> <u>AGA TTA AAT CGC ATA GGC CAC TAG TGG ATC TG</u>
PDC5-S1	<u>ATC AAT CTC AAA GAG AAC AAC ACA ATA CAA</u> <u>TAA CAA GAA GCA GCT GAA GCT TCG TAC GC</u>
PDC5-S2	<u>AAA ATA CAC AAA CGT TGA ATC ATG AGT TTT</u> <u>ATG TTA ATT AGC ATA GGC CAC TAG TGG ATC TG</u>
PDC6-S1	<u>TAA ATA AAA AAC CCA CGT AAT ATA GCA AAA</u> <u>ACA TAT TGC CCA GCT GAA GCT TCG TAC GC</u>
PDC6-S2	<u>TTT ATT TGC AAC AAT AAT TCG TTT GAG TAC</u> <u>ACT ACT AAT GGC ATA GGC CAC TAG TGG ATC TG</u>
PDC2-S1	<u>ACG CAA CTT GAA TTG GCA AAA TGG GCT TAT</u> <u>GAG ACG TTC CCA GCT GAA GCT TCG TAC GC</u>
PDC2-S2	<u>AGC CTG TGT TAC CAG GTA AGT GTA AGT TAT</u> <u>TAG AGT CTG GGC ATA GGC CAC TAG TGG ATC TG</u>

The PCR amplified deletion cassette was used for the transformation of the prototrophic diploid Saccharomyces cerevisiae strain CEN.PK122 developed by SRD.

5 CEN.PK 122 (Mata, alpha, URA3, URA3, HIS3, HIS3, LEU2,



LEU2, TRP1, TRP1, MAL2-8<sup>C</sup>, MAL2-8<sup>C</sup>, SUC2, SUC2)

For selection of transformants, geneticin (G-418 sulfate, Life Technologies) was added at a final concentration of 200 mg/l. After tetrad analysis, G418  
5 resistant spores were subsequently analyzed by diagnostic PCR to confirm the correct deletion of the corresponding *PDC* gene and to determine the mating type of the haploid strain.

To obtain a strain deleted for the three *PDC* genes,  
10 *PDC1*, *PDC5* and *PDC6*, the haploid deletion strains were subsequently crossed. To obtain the two double deletion strains, *pdcl::Kan<sup>SRD</sup>* *pdcl::Kan<sup>SRD</sup>* and *pdcl::Kan<sup>SRD</sup>* *pdcl::Kan<sup>SRD</sup>*, the corresponding haploid strains were crossed. After tetrad analysis, spores showing the non-  
15 parental ditype for the *Kan<sup>SRD</sup>* marker were subsequently analyzed by diagnostic PCR to confirm the correct deletion of both genes and to determine the mating type. The resulting double deletion strains were crossed to obtain the triple deletion strain. After tetrad analysis  
20 there was looked by diagnostic PCR for spores which are deleted for the three *PDC* genes.

To eliminate the *Kan<sup>SRD</sup>* marker from the successfully disrupted gene the haploid deletion strains (single, double and triple mutants) were transformed with the cre  
25 recombinase plasmid, *ppk-ILV2<sup>SMR</sup>* (developed by SRD). Plasmid *ppk-ILV2<sup>SMR</sup>* contains the cre-recombinase under the control of the *GAL1* promoter and as dominant selection marker the *ILV2* resistance gene, which allows yeast cells transformed with plasmid *ppk-ILV2<sup>SMR</sup>* to grow  
30 in the presence of sulfomethuron methyl (30mg/l). Correct excision of the *Kan<sup>SRD</sup>* marker was subsequently analyzed

38

by diagnostic PCR with whole yeast cells. To remove  
plasmid pPK-ILV2<sup>SMR</sup> the yeasts cells were incubated for  
an appropriate time without sulfomethuron methyl in the  
medium and subsequently searching for sulfomethuron  
5 methyl sensitive cells.

The following table shows the resulting yeast  
strains. The numbers in parentheses indicate the deleted  
nucleotides (ATG=1) of the corresponding genes. In the  
case of negative numbers means the first number the  
10 deleted nucleotides upstream of the ATG and the second  
number the deleted nucleotides downstream of the STOP  
codon.

Table

CEN.PK184	MATa	URA3	HIS3	LEU2	TRP1	<sup>c</sup>	SUC2	pdcl(-6,-2)::loxP
CEN.PK186	MATa	URA3	HIS3	LEU2	TRP1	MAL2-8 <sup>c</sup>	SUC2	pdcl(-6,-2)::loxP
CEN.PK210	MATa	URA3	HIS3	LEU2	TRP1	MAL2-8 <sup>c</sup>	SUC2	pdcl(-6,-2)::loxP
CEN.PK185	MATa	URA3	HIS3	LEU2	TRP1	MAL2-8 <sup>c</sup>	SUC2	pdcl(-6,-2)::loxP
CEN.PK183	MATa	URA3	HIS3	LEU2	TRP1	MAL2-8 <sup>c</sup>	SUC2	pdcl(-6,-2)::loxP
CEN.PK182	MATa	URA3	HIS3	LEU2	TRP1	MAL2-8 <sup>c</sup>	SUC2	pdcl(-6,-2)::loxP
								pdcl(-6,-2)::loxP
CEN.PK211	MATa	URA3	HIS3	LEU2	TRP1	MAL2-8 <sup>c</sup>	SUC2	pdcl(-6,-2)::loxP

Mainly we used the strains CEN.PK211 and CEN.PK182 which, in the tables summarizing the data obtained, are also named CENPK113 $\Delta$ PDC2 and CENPK113 $\Delta$ PDC1 $\Delta$ PDC5 $\Delta$ PDC6.

Using a similar approach a *S. cerevisiae* GRF18U strain  
5 (Mat alpha, his3, leu2, ura3) bearing a deletion in the PDC2 gene was build (GRF18U $\Delta$ PDC2; Mat alpha, his3, leu2, ura3, pdc2::APT1). We used the APT1 gene, conferring G418 resistance, as a marker of the integration, isolated from the plasmid pFA6a-KanMX (Wach et al. supra); For the  
10 strain bearing deletions in the PDC1, PDC5 and PDC6 genes, the PDC activity is zero. For the strains bearing a deletion in the PDC2 gene, the PDC activity is about 20-40% of the level determined in the wild-type strains.

Isolation of the *K. lactis* BM3-12D [pLAZ10]

15 A double deletant strain *Klpdc1* $\Delta$ /*Klpda1* $\Delta$  was selected from the haploid segregant population of a diploid strain obtained by crossing strain MW341-5/*Klpdc1* $\Delta$  (MAT $\alpha$ , *lac4-8*, *leu2*, *lysA1-1*, *uraA1-1*, *Klpdc1*::*URA3*; obtained as previously described in Bianchi et. al, 1996, Mol.  
20 Microbiol. 19 (1), 27-36; Destruelle et al., submitted) with strain CBS2359/*Klpda1* $\Delta$  (MAT $\alpha$ , *URA3-48*, *Klpda1*::*Tn5BLE*) Deletion of the *PDA1* gene, encoding for the pyruvate dehydrogenase complex E1-alpha subunit (EC.1.2.4.1)(the DNA sequence has been obtained by  
25 Steensma H.Y.; Faculty of Mathematics and Natural Sciences, Clusius Laboratory, Leiden, The Netherland- the DNA sequence is also available at the accession n. AF023920 of the Genbank Sequence Database provided by the National Center of Biotechnology -NCBI- Web site:  
30 <http://www.ncbi.nlm.nih.gov/>), in the yeast strain CBS2359 has been obtained following the classical PCR

approach and yeast transformation described throughout the text. We used the marker Tn5Ble (Gatignol et al., Gene, 91: 35, 1990) conferring phleomycin resistance, as a marker of the integration.

5       The double deletant strain, called BM1-3C (MATa, *leu2*, *Klpdc1::URA3*; *Klpda1::Tn5BLE*), was selected as a phleomycin resistant/antimycin sensitive segregant strain. The vector pLAZ10 was then genetically transferred to the double deletant strain as follows.

10       A pLAZ10 transformant of the *Klpdc1::URA3* strain PMI/8 (MATa, *adeT-600*, *uraA1-1*, *Klpdc1::URA3*; Bianchi et al., Mol. Microbiol. 19:27-36, 1996) was crossed with strain MW109-8C (MATa, *lysA1-1*, *trpA1-1*). After sporulation of the resulting diploid strain, a geneticin  
15 resistant/antimycin sensitive strain, called strain 7C (MATa, *adeT-600*, *lysA1-1*, *Klpdc1::URA3*, pLAZ10<sup>+</sup>), was selected.

Strain BM1-3C and strain 7C were crossed and phleomycin resistant/geneticin resistant haploid  
20 segregant strains were selected after sporulation of the obtained diploid strain. All of the haploid segregants were antimycin sensitive. The prototroph strain BM3-12D (*Klpdc1::URA3*; *Klpda1::Tn5BLE*, pLAZ10<sup>+</sup>) was chosen for further experiments.

25       Transformation of Kluyveromyces yeast PM6-7A and PMI/C1 with the vectors pEPL2 and pEPL4.

PM6-7A and PMI/C1 cells were grown in YPD medium until a concentration of  $0.5 \times 10^8$  cells/ml; harvested, washed once in water, twice in 1M sorbitol, and  
30 resuspended in 1M sorbitol at a concentration of  $2 \times 10^9$  cells/ml. Cells were electroporated (7.5 KV/cm, 25  $\mu$ F,

200  $\Omega$ : GenePulser, Biorad, Hercules, Ca) in the presence of 5-10 microg of pEPL2 or pEPL4. Selection of URA<sup>+</sup> transformants was carried out in synthetic solid medium without uracil (0.7 % w/v Yeast Nitrogen Base, 2 w/v % glucose, 200 mg/l adenine, 2 w/v % agar).

Transformation of Torulaspora yeast with the vector pLAT-ADH

CBS817 cells were grown in YPD medium until a concentration of  $6 \times 10^7$  cells/ml, harvested, washed once in water, twice in 1M sorbitol, and resuspended in 1M sorbitol at a concentration of  $2 \times 10^9$  cells/ml. Cells were electroporated (1.5 kV, 7.5 KV/cm, 25 pF, 200  $\Omega$ : GenePulser, Biorad, Hercules, Ca) in the presence of 1  $\mu$ g of pLAT-ADH.

Cells were grown overnight in sterile microbiological tubes containing 5 ml of YEPD, Sorbitol 1M. Selection of G418<sup>r</sup> transformants was carried out in solid medium (2 w/v % glucose, 2 w/v % Peptone, 1 w/v % Yeast extract, 2 w/v % agar, 200  $\mu$ g/ml G418 (Gibco BRL, cat. 11811-031).

Transformation of Zygosaccharomyces yeasts with the vector pLAT-ADH.

ATTC36947 and ATTC60483 cells were grown in YPD medium until a concentration of  $2 \times 10^8$  cells/ml, harvested, and resuspended at a concentration of  $4 \times 10^8$  cells/ml in 0.1M lithium acetate, 10 mM dithiothreitol, 10 mM Tris-HCl, pH 7.5 at room temperature for one hour. The cells were washed once in water, twice in 1M sorbitol, and resuspended in 1M sorbitol at a concentration of  $5 \times 10^9$  cells/ml. Cells were electroporated (1.5 kV, 7.5 KV/cm, 25 pF, 200  $\Omega$ :

GenePulser, Biorad, Hercules, Ca) in the presence of 3 µg of pLAT-ADH.

Cells were grown overnight in sterile microbiological tubes containing 5 ml of YEPD, Sorbitol 1M. Selection of G418<sup>r</sup> transformants was carried out in solid medium (2 w/v % glucose, 2 w/v % Peptone, 1 w/v % Yeast extract, 2 w/v % agar, 200 µg/ml G418 (Gibco BRL, cat. 11811-031)).

Transformation of Saccharomyces yeast cells with the vectors pLC5, PLC7, pB1, pBST2, pBME2, pLAT-ADH, pLC5-kanMX and pJEN1

GRF18U (described above), GRF18UAPDC2 (described above), GRF18U[pLC5] (Mat alpha, his3, leu2, ura3::TPI-LDH), CENPK113 (Mat a; CBS8340), CENPK-1 (Mat a, ura3), CENPK113ΔPDC1ΔPDC5ΔPDC6 (described above) and CENPK113ΔPDC2 (described above) yeast cells were grown in rich YPD complete medium (2% w/v yeast extract, 1% w/v peptone, 2% w/v glucose) until a concentration of  $2 \times 10^7$  cells/ml, washed once in 0.1M lithium acetate, 1 mM EDTA, 10 mM Tris-HCl, pH 8, harvested, and resuspended in 0.1M lithium acetate, 1 mM EDTA, 10 mM Tris-HCl, pH 8, at a concentration of  $2 \times 10^9$  cells/ml. 100 µl of the cellular suspension were incubated 5 minutes with 5-10 µg of vector (i.e, previously linearized in the auxotrophic marker in the case of pLC5, PLC7, pB1, pBST2, pBME2, pLC5-kanMX, pJEN1). After the addition of 280 µl of PEG 4000, the cells were incubated for at least 45' at 30°. 43 µl of DMSO were added and the suspension was incubated 5' at 42°. The cells were washed twice with water and plated onto selective medium. For the isolation of CENPK-1 strain (ura3), CENPK113 cells were grown in media

containing 5-fluororotic acid (see also above).

Single transformed clones were scored with 0.7 % w/v Yeast Nitrogen Base, 2 w/v % glucose, 2 w/v % agar plus the appropriate supplements or G418 as indicated. For  
5 selection of G418<sup>R</sup> transformants, cells were also scored on 2 w/v % glucose, 2 w/v % Peptone, 1 w/v % Yeast extract, 2 w/v % agar, 200 µg/ml G418 (Gibco BRL, cat. 11811-031).

Transformed strain: supplements.

10 GRF18U[pLAT-ADH]: 200 mg/l uracile, 200 mg/l leucine, 200 mg/l histidine, 200 mg/l G418.

GRF18U[pB1]:200 mg/l leucine, 200 mg/l histidine.

GRF18U[pLC5]:200 mg/l leucine, 200 mg/l histidine.

GRF18U[pLC5][pLC7]:200 mg/l leucine.

15 GRF18U[pBM2]:200 mg/l leucine, 200 mg/l histidine.

GRF18U[pBST2]:200 mg/l leucine, 200 mg/l histidine.

GRF18U[pLC5][pJEN1]:200 mg/l leucine.

GRF18UΔPDC2[pLC5]: 200 mg/l leucine, 200 mg/l histidine.

CENPK-1[pLC5]:no supplements

20 CENPK113[pLC5-KanMX]: 200 mg/l G418

CENPK113ΔPDC1ΔPDC5ΔPDC6[pLC5-KanMX]: 200 mg/l G418

CENPK113ΔPDC2[pLC5-KanMX]: 200 mg/l G418

List of the expression vectors used:

Name:	LDH source	promoter	Host, Selective marker
25 pEPL2	Bovine	KLPDCA	<u>K. Lactis</u> , URA3.(fig. 4)
pEPL4	L. casei	KLPDCA	<u>K. Lactis</u> , URA3.
PLAZ10	Bovine	KLPDCA	<u>K. Lactis</u> , APT1.
pLC5	L. casei	SCTPI	<u>S. cerevisiae</u> , URA3. (fig. 5)
30 pLC5-kanMx	L. casei	SCTPI	<u>S. cerevisiae</u> , APT1.
pBME2	B. megate- rium	SCTPI	<u>S. cerevisiae</u> , URA3.
pBST2	B. Ste.-	SCTPI	<u>S. cerevisiae</u> , URA3.
pB1	Bovine	SCTPI	<u>S. cerevisiae</u> , URA3.



45

pLC7	L. casei	SCTPI	<u>S. cerevisiae</u> , HIS3.
pJEN1	/////	SCTPI	<u>S. cerevisiae</u> , HIS3.
pLAT-ADH	Bovine	SCADH1	<u>S. cerevisiae</u> ,
			APT1-URA3(fig. 6)
5			<u>T. delbrueckii</u> , APT1-URA3,
			<u>Z. bailii</u> , APT1-URA3.

KL= K. lactis's promoterSC= S. cerevisiae's promoterB. Ste.= Bacillus stearothermophilus

10 pJEN1 has been used for the overexpression of the JEN1 gene.

BATCH TESTS

Batch analysis of Kluyveromyces PM6-7A[pEPL2],  
PMI/C1[pEPL2], PM6-7A[pEPL4] and PMI/C1[pEPL4]  
 15 transformed cells.

Clones obtained by the transformation procedure above described were tested in batch culture during growth on minimum synthetic medium (1.3% w/v Yeast Nitrogen Base - aa (Difco, Detroit, MI), 200 mg/l adenine, 50 g/l  
 20 glucose). The media used were both buffered or not with 200mM phosphate buffer to a pH of 5.6.

Cells were preinoculated in the same test's medium. Exponentially growing cells were inoculated in flask (300 ml volume) containing 100 ml of fresh medium. The flasks  
 25 were incubated at 30° C in a shaking bath (Dubnoff, 150 rpm), and fermentation was monitored at regular time points. Cell number concentration was determined with an electronic Coulter counter (Coulter Counter ZBI Coulter Electronics Harpenden, GB, Porro et al., Res. Microbiol.  
 30 (1991) 142, 535-539), after sonication of the samples to avoid cellular aggregates (Sonicator Fisher 300, medium point, Power 35%, 10 seconds)(Fig. 7 and 8 and Tab.3)

Batch analysis of Kluyveromyces BM3-12D[pLAZ10] transformed cells.

Clones obtained by the procedure above described were tested in batch culture during growth on minimum synthetic medium (1.3% w/v Yeast Nitrogen Base -aa (Difco, Detroit, MI), 50 g/l glucose, 20 gr/l ethanol, 200 mg/l G418). The media used were buffered with 200mM phosphate buffer to a pH of 5.6.

Cells were preinoculated in the same test's medium. Exponentially growing cells were inoculated in flask (300 ml volume) containing 100 ml of fresh medium. The flasks were incubated at 30° C in a shaking bath (Dubnoff, 150 rpm), and fermentation was monitored at regular intervals. Cell number concentration was determined with an electronic Coulter counter (Coulter Counter ZBI Coulter Electronics Harpenden, GB, Porro et al., Res. Microbiol. (1991) 142, 535-539), after sonication of the samples to avoid cellular aggregates (Sonicator Fisher 300, medium point, Power 35%, 10 seconds). At the beginning, cells used ethanol and then transformed glucose to lactic acid with very high yield (>0.75; g of lactic acid/g glucose consumed) (Tab.3).

Batch analysis of Torulaspora CBS817[pLAT-ADH] transformed cells.

Clones obtained by the transformation procedure above described were tested in batch culture during growth on minimum synthetic medium (1.3% w/v Yeast Nitrogen Base -aa (Difco, Detroit, MI), 20 g/l glucose, 200 mg/l G418). The media used were not buffered.

Cells were preinoculated in the same test's medium. Exponentially growing cells were inoculated in flask (300

ml volume) containing 100 ml of fresh medium. The flasks were incubated at 30° C in a shaking bath (Dubnoff, 150 rpm), and fermentation was monitored at regular intervals. Cell number concentration was determined with  
5 an electronic Coulter counter (Coulter Counter ZBI Coulter Electronics Harpenden, GB, Porro et al., Res. Microbiol. (1991) 142, 535-539), after sonication of the samples to avoid cellular aggregates (Sonicator Fisher 300, medium point, Power 35%, 10 seconds)(Fig. 10 and  
10 Tab.3)

Batch analysis of Zygosaccharomyces ATCC36947[pLAT-ADH] and ATCC60483[pLAT-ADH] transformed cells.

Clones obtained by the transformation procedure above described were tested in batch culture during growth on  
15 minimum synthetic medium (1.3% w/v Yeast Nitrogen Base - aa (Difco, Detroit, MI), 50 g/l glucose, 200 mg/l G418). The media used were not buffered.

Cells were preinoculated in the same test's medium. Exponentially growing cells were inoculated in flask (300  
20 ml volume) containing 100 ml of fresh medium. The flasks were incubated at 30° C in a shaking bath (Dubnoff, 150 rpm), and fermentation was monitored at regular intervals. Cell number concentration was determined with an electronic Coulter counter (Coulter Counter ZBI  
25 Coulter Electronics Harpenden, GB, Porro et al., Res. Microbiol. (1991) 142, 535-539), after sonication of the samples to avoid cellular aggregates (Sonicator Fisher 300, medium point, Power 35%, 10 seconds)(Fig. 11 and Tab.3).

30 Batch analysis of Saccharomyces GRF18U[pLAT-ADH], GRF18U[pB1], GRF18U[pLC5], GRF18U[pLC5][pLC7],

GRF18U[pBM2], GRF18U[pBST2], CENPK-1[pLC5] transformed cells.

Clones obtained by the transformation procedure above described were tested in batch culture during growth on minimum synthetic medium (1.3% w/v Yeast Nitrogen Base - aa (Difco, Detroit, MI), 50 g/l glucose and appropriate supplements (see above). The media used were not buffered. Cells were preinoculated in the same test's medium. Exponentially growing cells were inoculated in flask (300 ml volume) containing 100 ml of fresh medium. The flasks were incubated at 30° C in a shaking bath (Dubnoff, 150 rpm), and fermentation was monitored at regular intervals. Cell number concentration was determined with an electronic Coulter counter (Coulter Counter ZBI Coulter Electronics Harpenden, GB, Porro et al., Res. Microbiol. (1991) 142, 535-539), after sonication of the samples to avoid cellular aggregates (Sonicator Fisher 300, medium point, Power 35%, 10 seconds)(Tab.3).

Batch analysis -spinner flask- of Saccharomyces, GRF18UAPDC2[pLC5], CENPK113[pLC5-kanMX], CENPK113APDC2[pLC5-kanMX] and CENPK113APDC1 Δ PDC5APDC6[pLC5-kanMX] transformed cells.

Clones obtained by the procedures above described were tested in batch culture during growth on rich medium (1.0% w/v Yeast Extract, 2% w/v Peptone, 100 gr/l glucose). The media were not buffered.

Cells were preinoculated on Yeast Extract-Peptone + ethanol (5g/l) media. 100 ml were inoculated in spinner flasks (1.5 l working volume; initial pH=5.7). The spinner flasks were incubated at 30° C, agitation: 55

rmf. Fermentation was monitored at regular intervals (Tables A,B,C and Table 3).

The LDH specific activity from the different transformed strains, was higher than 5 U/mg of total cell proteins.

LDH activity dosage

Bovine LDH. About  $10^8$  cells were harvested, washed in 50mM phosphate buffer, pH 7.5, and resuspended in the same buffer. Cells were lysed with 5 cycles of vigorous vortexing in presence of glass microbeads (diameter 400  $\mu$ m, SIGMA, G-8772) at 4° C. Cellular debris were removed by centrifugation (Eppendorf, Hamburg, D 5415 C, 13600 RCF, 10 min), and protein extracts' concentration was determined by Micro Assay, Biorad, Hercules, Ca (cat. 500-0006).

About 0.2 mg of extract were tested for LDH activity using SIGMA (St. Louis, MO) kit DG1340-UV, according to manufacturer's instructions.

Bacterial LDHs. About  $10^8$  cells were harvested, washed in 50mM phosphate buffer, pH 7.5, and resuspended in the same buffer. Cells were lysed with 5 cycles of vigorous vortexing in presence of glass microbeads (diameter 400  $\mu$ m, SIGMA, G-8772) at 4° C. Cellular debris were removed by centrifugation (Eppendorf, Hamburg, D 5415 C, 13600 RCF, 10 min), and protein extracts' concentration was determined by Micro Assay, Biorad, Hercules, Ca (cat. 500-0006).

Cellular extract was tested for LDH activity using:

0,01 ml of 12.8 mM NADH

0,1 ml of 2 mM fructose1,6 -diphosphate

0.74 ml of 50 mM acetate buffer (pH=5,6)

50

0,05 ml of properly diluted cell extract and

0,1 ml sodium pyruvate 100 mM.

LDH activity was assayed as micromoles of NADH  
oxidased per min, per mg of total cell extract at 340 nm,  
5 25 °C.

Metabolites dosage in the growth medium.

Samples from the growth medium, obtained after  
removing cells by centrifugation, were analysed for the  
presence of glucose, ethanol, L(+)- and D(-)-lactic acid  
10 using kits from Boehringer Mannheim, Mannheim DE, (#.  
716251, 176290, and 1112821 respectively), according to  
manufacturer's instructions.

Experimental batch tests related to the Kluyveromyces  
PM6-7A[pEPL2] and PMI/C1[pEPL2] transformed yeasts are  
15 shown in figures 7A, 7B and figures 8A, 8B.

Experimental data related to the Torulaspora  
CBS817[pLAT-ADH] transformed yeasts are shown in figure  
10.

Experimental data related to the Zygosaccharomyces  
20 ATCC60483 [pLAT-ADH] transformed yeasts are shown in  
figure 11.

Experimental data related to the Saccharomyces  
CENPK113[pLC5-KanMX] CENPK113 ΔPDC2[pLC5-kanMX] and  
CENPK113ΔPDC1ΔPDC5ΔPDC6 [pLC5-kanMX] transformed yeasts  
25 growing in spinner-flask are shown in Tables A,B,C.

Table AOverview of the cultivation with *S. cerevisiae* (CENPK113[pLC5-KanMX])

Time [h]	pH	OD <sub>660</sub>	glucose[g.l <sup>-1</sup> ]	ethanol[g.l <sup>-1</sup> ]	lactate[g.l <sup>-1</sup> ]
0.0	5.76	0.31	88.4 ± 0.3	0.2	0
19.0	3.01	8.7 ± 0.2	6.5 ± 0.1	25	27.4 ± 0.2
25.0	3.05	10.41 ± 0.01	0.4 ± 0.2	27	30.1 ± 0.4
45.25	3.07	13.2 ± 0.2	0.06 ± 0.03	27	31.1 ± 0.2
70.75	3.08	10.6 ± 0.3	0	26	30.7 ± 0.1
92.0	3.08	12.2 ± 0.8	0	26	29.5 ± 0.1

Table BOverview of the cultivation with *S. cerevisiae* (CEN.PK113  $\Delta$ pdc2[pLC5-KanMX])

Time [h]	pH	OD <sub>660</sub>	glucose[g.l <sup>-1</sup> ]	ethanol[g.l <sup>-1</sup> ]	lactate[g.l <sup>-1</sup> ]
0.0	5.75	0.32	87 ± 0.4	0.2	0
19.0	3.20	2.2 ± 0.2	47.8 ± 0.1	8	17.3 ± 0.1
25.0	3.07	4.45 ± 0.1	36.3 ± 0.1	11	25.4 ± 0.1
45.25	2.96	5.31 ± 0.02	24.0 ± 0.1	15	38.0 ± 0.1
70.75	2.98	4.8 ± 0.1	12.9 ± 0.1	19	42.4 ± 0.4
92.0	2.95	5.3 ± 0.1	8.47 ± 0.01	24	43.1 ± 0.1



Table C

Overview of the cultivation with *S. cerevisiae* (CENPK113  $\Delta$ pdcl  $\Delta$ pdcs  $\Delta$ pdcs6 [pLC5-KanMX])

Time [h]	pH	OD660	glucose[g.l <sup>-1</sup> ]	ethanol[g.l <sup>-1</sup> ]	lactate[g.l <sup>-1</sup> ]
0.0	5.74	0.82 ± 0.01	92 ± 1		0.171 ± 0.005
10.0	5.16	1.185 ± 0.02	93 ± 1		0.715 ± 0.0
23.5	4.61	1.28 ± 0.03	94 ± 2		1.76 ± 0.1
49.25	4.05	1.36 ± 0.03	92.8 ± 0.8		3.614 ± 0.005
73.0	3.79	1.27 ± 0.03	89.0 ± 0.7		5.17 ± 0.01
106.0	3.60	1.25 ± 0.02	80 ± 2		6.84 ± 0.06
122.5	3.57	81.24 ± 0.06	1.23 ± 0.05	0	7.596 ± 0.006
167.0	3.43	75 ± 1	1.17 ± 0.08		8.5 ± 0.2

All the results obtained from transformed Kluyveromyces, Torulaspora, Zygosaccharomyces and Saccharomyces yeasts are summarized and compared in Table 3. The yield is the amount of lactic acid produced (gr/l) divided by the amount of glucose consumed (gr/l). The percentage of free lactic acid is obtained from the Henderson-Hasselbalch equation:  $\text{pH} = \text{pK}_a + \log[(\% \text{Lactate})/(\% \text{Free Lactic Acid})]$ , where the  $\text{pK}_a$  for lactic acid is 3.86.

Comparison of the data reported in Table 3A Vs Table 3B clearly proves that in different yeasts genera, the production of lactic acid with higher yield on glucose can be obtained by changing the relative ratio -at cellular level- of the LDH and PDC activities. Such goal can be obtained following at least two different approaches:

- (1) by reducing the PDC activity (compare data from transformed K. lactis hosts: PM6-7A Vs PMI/CI; compare data from transformed S. cerevisiae hosts GRF18U Vs GRF18 $\Delta$ PDC2 and CENPK113 Vs CENPK113 $\Delta$ PDC2 and CENPK113 $\Delta$ PDC1 $\Delta$ PDC5 $\Delta$ PDC6)
- (2) by increasing the LDH gene copy number and therefore the LDH activity (compare data from S. cerevisiae host: GRF18U[pLC5] Vs GRF18U[pLC5][pLC7]; the LDH heterologous activity in the two strains is 5-6 and 7-8 U/mg of total cell proteins, respectively).

Further, higher yields can be obtained by manipulating the composition of the growth medium. Also in this case, a reduced ethanol production was observed (see also Table 4).

Table 3A

Table 3A. BATCH TESTS. Lactic Acid Production from transformed *Kluyveromyces lactis*, *Torulaspora delbrueckii*, *Zygosaccharomyces bailii* and *Saccharomyces cerevisiae* yeasts bearing a heterologous LDH gene.

	Phosphate Buffer	Lactic Acid (g/L)	Yield (g/g)	Final pH	% Free Lactic Acid
<u>Kluyveromyces yeasts</u>					
PM6-7A (negative control)	-	0.0	0.000	2.5	00
PM6-7A[pEPL2] (Fig.7)	-	1.2	0.024	2.0	99
PM6-7A[pEPL2] (Fig.7)	+	4.3	0.087	3.0	88
PM6-7A[pEPL4]	-	1.1	0.022	2.1	99
PM6-7A[pEPL4]	+	4.5	0.090	3.0	88
<u>Torulaspora yeasts</u>					
CBS817(negative control)	-	0.0	0.000	2.9	00
CBS817[pLAT-ADH] (Fig.10)	-	1.0	0.058	2.8	92
<u>Zygosaccharomyces yeasts</u>					
ATCC60483(negative control)	-	0.0	0.000	2.5	00
ATCC60483[pLAT-ADH] (Fig.11)	-	1.2	0.029	2.4	96
ATCC36947(negative control)	-	0.0	0.000	2.5	00
ATCC36947[pLAT-ADH]	-	0.9	0.018	2.4	95

Table 3A (continuing)

	<u>Phosphate</u> <u>Buffer</u>	<u>Lactic Acid</u> <u>(g/L)</u>	<u>Yield</u> <u>(g/g)</u>	<u>Final pH</u>	<u>% Free</u> <u>Lactic Acid</u>
GRF18U(negative control)	-	0.0	0.000	3.1	00
GRF18U[pLAT-ADH]	-	2.1	0.040	3.0	88
GRF18U[pLC5]	-	8.297	0.165	3.0	88
GRF18U[pBME2]	-	5.927	0.118	3.0	88
GRF18U[pBST2]	-	0.320	0.06	3.1	87
GRF18U[pB1]	-	1.5	0.020	3.0	88
CENPK-1[pLC5]	-	1.8	0.030	3.0	88
**CENPK113[pLC5-KanMX]	-	29.5	0.338	3.0	88

Saccharomyces yeasts

Table 3B

Table 3B. BATCH TESTS. Lactic acid yield can be improved by both genetic and physiological approaches (compare with table 3A).

	Phosphate Buffer	Lactic Acid (g/L)	Yield (g/g)	Final pH	% Free Lactic Acid
<u>Kluyveromyces yeasts:</u>					
PMI/C1ΔPDCA[pEPL2] (Fig.8)	-	2.0	0.052	2.3	97
PMI/C1ΔPDCA[pEPL2] (Fig.8)	+	11.4	0.233	2.9	90
PMI/C1ΔPDCA[pEPL4]	-	2.1	0.053	2.3	97
PMI/C1ΔPDCA[pEPL4]	+	11.0	0.231	2.9	90
BM3-12D[pLAZ10]	+	20.5	0.757	3.5	70
<u>Saccharomyces yeasts</u>					
GRF18U[pLC5][pLC7]	-	9.867	0.197	3.0	88
**GRF18UΔPDC2[pLC5]	-	30.2	0.347	3.0	88
**CENPK113 ΔPDC2[pLC5-KanMX]	-	43.1	0.549	2.9	88
**CENPK113 ΔPDC1,Δ5,Δ6[pLC5-KanMX]	-	8.5	0.500	3.4	73
§GRF18U[pLC5][pLC7] (§: see also Table 4 for more details about this last data)	-	13.74	0.29	3.0	88

\*\* data obtained in spinner flask, under partial anaerobic conditions (see also Tables A,B,C)

Experimental data related to the *Saccharomyces* GRF18[pLC5][pLC7] growing in a manipulated mineral medium (Table 4).

Lactic acid production by *Saccharomyces* GRF18U[pLC5][pLC7] transformed cells was also carried out growing the cells in a synthetic medium (D. Porro et al., Development of a pH controlled fed-batch system for budding yeast. Res. in Microbiol., 142, 535-539, 1991). In the synthetic medium used, the source of Mg and Zn salts are MgSO<sub>4</sub> (5 mM) and ZnSO<sub>4</sub> x 7H<sub>2</sub>O (0.02 mM), respectively. Production was tested in aerobic batch culture (glucose concentration 50 gr/l) as above described for the other transformed *Saccharomyces* cells. It has been found that depletion of both MgSO<sub>4</sub> and ZnSO<sub>4</sub> x 7H<sub>2</sub>O yielded higher yield and higher lactic acid productivities. In fact, these minerals could be required as cofactor for the enzymatic activities leading to ethanol production. Data are shown in Table 4.

Table 4. L(+) L-lactic acid production by *Saccharomyces* GRF18[pLC5][pLC7] transformed cells during batch growth in manipulated mineral media.

	Control	-Mg	-Zn
Lactic acid production, g/l	9.23	13.74	13.74
Yield, g/g	0.20	0.29	0.29
Productivity, g/l,hr	0.38	0.42	0.61
Ratio ethanol/lactic acid, mM/mM	2.78	2.11	1.99

Legend:

Control: complete synthetic medium (Res. in Microbiol., 142, 535-539, 1991; enclosed)

-Mg: identical to the control but with out MgSO<sub>4</sub>

-Zn: identical to the control but with out  $\text{ZnSO}_4 \times 7\text{H}_2\text{O}$

For all the tests, the final pH value was lower than 3.0 and therefore the % of free lactic acid was higher than 88%.

5        Lactic acid production by yeast cells overexpressing the JEN1 gene.

Better lactic acid productions and lower ethanol productions have been obtained by overexpression of the JEN1 gene, encoding for the lactate transporter.

10       GRF18U[pLC5] (i.e., negative control) and GRF18U[pLC5][pJEN1] have been grown in media containing 2% glucose, 0,67 % YNB w/v and supplements (i.e., 100 mg/l leucine-histidine, and 100 mg/l leucine, respectively).

15       Cells were preinoculated in the same test's medium. Exponentially growing cells were inoculated in flask (300 ml volume) containing 100 ml of fresh medium. The flasks were incubated at 30° C in a shaking bath (Dubnoff, 150 rpm), and fermentation was monitored at regular  
20 intervals. Cell number concentration was determined with an electronic Coulter counter (Coulter Counter ZBI Coulter Electronics Harpenden, GB, Porro et al., Res. Microbiol. (1991) 142, 535-539), after sonication of the  
25 300, medium point, Power 35%, 10 seconds).

Table 5. Comparison of lactate and ethanol productions during batch cultures

Strain	Lactate	Ethanol
	g/l	g/l
30 GRF18U[pLC5]	3,33	4,39
GRF18U[pLC5][pJEN1]	6,06	4,23

Continuous lactic acid production.

Continuous and stable productions of lactic acid have been obtained for more than 2 weeks by means of classical chemostat cultures (the continuous flow of fresh medium to the bioreactor supported specific growth rate ranging  
5 between 0,01 and 0,3 hr<sup>-1</sup>) using both the transformed K. lactis PM6-7A[pEPL2], PMI/CI[pEPL2] and the transformed S. cerevisiae GRF18U[pLC5][pLC7] strains.

FED-BATCH TESTS

10 Lactic Acid Production by PMI/C1[pEPL2] in a Stirred-tank Fermentor

Lactic acid production by PMI/C1[pEPL2] was further tested by cultivation in a 14-liter stirred-tank fermentor containing 8 liters of nutrient medium (30 g  
15 dry solids/L light corn steep water, A.E. Staley Manufacturing Co., Decatur, IL; 10 g/L Difco yeast extract, Difco, Detroit, MI; 200 mg/L adenine, 50 g/L glucose). The fermentor was kept at 30° C, agitated at 400 rpm, and aerated at 2 liters/min throughout.  
20 Antifoam (Antifoam 1520, Dow Corning Corp., Midland, MI) was added as needed to control foaming. Glucose was fed as needed to maintain a residual concentration in the fermentation medium of about 25-50 g/L. When controlled, the pH was maintained by automatic addition of 14.8 M  
25 ammonium hydroxide in water. Lactic acid production at acidic pH was tested as follows: (1) The fermentation pH was controlled at 4.5 throughout the fermentation. (2) The initial fermentation pH was controlled at 4.0 until 80 mL of 14.8 M ammonium hydroxide were added. Then pH  
30 control was discontinued. (3) The initial fermentation pH was 5.0 and no neutralizing agent was added during the



fermentation. The results are shown in Table 6. The elapsed time was measured from the time of inoculation. Samples from the fermentation, obtained after removing cells by filtration, were analyzed for the presence of glucose and L(+)-lactic acid using a YSI Model 2700 Select Biochemistry Analyzer (Yellow Springs Instrument Co., Inc., Yellow Springs, OH). Ethanol, measured by gas chromatography, was not detected in any of the fermentations. Yield and % free lactic acid were calculated as previously described. Inocula for the fermentations were prepared by pre-culturing PMI/C1[pEPL2] in 50 mL of minimum synthetic medium (1.3% w/v Yeast Nitrogen Base -aa (Difco, Detroit, MI), 200 mg/L adenine, 5 g/L ammonium sulfate, 50 g/L glucose) in a 250 mL baffled Erlenmeyer flasks for 30 hr at 30° C and 300 rpm in an incubator shaker (Model G-24, New Brunswick Scientific Co., Inc., Edison, NJ).

Similar results were obtained using the bacterial LDH gene (plasmid pEPL4; data not shown).

Table 6. Lactic Acid Production by *Kluyveromyces* PMI/C1[pEPL2] cells in a Fermentor.

	Elapsed Time (hr)	NH <sub>4</sub> OH Added (M)	Lactic Acid Yield		Final pH	% Free Lactic Acid
			(g/L)	(g/g)		
Case 1	137	1.31	109	0.59	4.5	19
Case 2	97	0.14	35	0.44	3.0	88
Case 3	72	0	29	0.35	2.8	92

Lactic Acid Production by BM3-12D[pLAZ10] in a Stirred-tank Fermentor.

Lactic acid production by BM3-12D[pLAZ10] was further

tested by cultivation in a 1 liter stirred-tank fermentor containing 0.8 liters of nutrient medium (6,7 gr/ YNB /Yeast Nitrogen Base- Difco, Detroit, MI, 45 g/L glucose, 2% v/v ethanol, G418 200 mg/l). The fermentor was kept  
5 at 30° C, agitated at 400 rpm, and aerated at 0.8 liters/min throughout. Antifoam (Antifoam 1520, Dow Corning Corp., Midland, MI) was added as needed to control foaming. Transformed cells first used ethanol for the production of biomass (first 50 hrs of growth) and  
10 then transformed glucose to L(+) Lactic acid. The pH was maintained at 4.5 by automatic addition of 2 M KOH. Glucose was fed as needed to maintain a residual concentration in the fermentation medium of about 35-45 g/L

15 The results are shown in figure 9 and Table 7 (Case 1). The elapsed time was measured from the time of inoculation. Samples from the fermentation, obtained after removing cells by filtration, were analyzed for the presence of glucose, ethanol and L(+)-lactic acid using a  
20 standard enzymatic analysis as described in Porro et al. 1995 (supra). After T=50 hr, ethanol was not detected in any of sample-test. Yield and % free lactic acid were calculated as previously described.

Inocula for the fermentations were prepared by pre-  
25 culturing BM3-12D[pLAZ10] in 50 mL of minimum synthetic medium (1.3% w/v Yeast Nitrogen Base -aa (Difco, Detroit, MI), 2 % v/v ethanol, G418 200 mg/l) in a 250 mL baffled Erlenmeyer flasks for 40 hr at 30° C and 300 rpm in an incubator shaker (Model G-24, New Brunswick Scientific  
30 Co., Inc., Edison, NJ).

In a different experiment (Table 7, Case 2), the

63

initial fermentation pH was 5.4 and no neutralizing agent was added during the fermentation.

Table 7. Lactic Acid Production by *Kluyveromyces* BM3-12D[pLAZ10] cells in Fermentor.

		Lactic				
		Elapsed	Acid	Yield	% Free	
		<u>Time (hr)</u>	<u>(g/L)</u>	<u>(g/g)</u>	<u>Final pH</u>	<u>Lactic</u>
						<u>Acid</u>
	Case 1	474	60.3	0.854	4.5	19
10	Case 2	498	32.3	0.881	3.6	65

CLAIMS

1. A yeast strain lacking ethanol production ability or having a reduced ethanol production ability with respect  
5 to wild-type yeasts of the same strains and transformed with at least one copy of a gene coding for lactic dehydrogenase, functionally linked to promoter sequences allowing the expression of said gene in yeasts.
2. A yeast strain according to claim 1 having an  
10 ethanol production ability which is less than about 60% compared to wild type yeasts of the same strain.
3. A yeast strain according to claim 1 or 2 having a reduced pyruvate decarboxylase and/or pyruvate dehydrogenase activities and at least one copy of a  
15 nucleic acid sequence encoding for lactic dehydrogenase protein.
4. A yeast strain according to claim 3 having a reduced pyruvate dehydrogenase activity.
5. A yeast strain according to claim 3 having a reduced  
20 pyruvate decarboxylase activity.
6. A yeast strain according to claim 3 having both a reduced pyruvate dehydrogenase activity and a reduced pyruvate decarboxylase activity.
7. A yeast strain according to any one of claims 1-6  
25 wherein the gene or the genes coding for pyruvate decarboxylase, for pyruvate dehydrogenase or both has or have been disrupted by deletion or insertion by means of selectable marker(s).
8. A yeast strain according to claim 7, wherein the  
30 selectable marker is a URA3 marker.
9. A yeast strain according to claim 8 wherein the

selectable marker is the URA3 marker from Saccharomyces cerevisiae.

10. A yeast strain according to claim 7, wherein the selectable marker is a dominant marker encoding for resistance to toxic compounds.
11. A yeast strain according to any one of claims 1-10, selected from Saccharomyces, Kluyveromyces, Torulaspora and Zygosaccharomyces species.
12. A yeast strain according to claim 11 which is a strain of Saccharomices cerevisise.
13. A yeast strain according to claim 11 which is a strain of Kluyveromyces lactis.
14. A yeast strain according to claim 11 which is a strain of Torulaspora delbrueckii.
15. A yeast strain according to claim 11 which is a strain of Zygosaccharomyces bailii.
16. A yeast strain selected from Kluyveromyces, Torulaspora and Zygosaccharomyces species transformed with at least one copy of a gene coding for lactic dehydrogenase, functionally linked to promoter sequences allowing the expression of said gene in said yeasts.
17. A yeast strain according to any one of claims 1 to 16 transformed with a gene coding for the bovine lactate dehydrogenase.
18. A yeast strain according to any one of claims 1 to 16 transformed with a gene coding for a bacterial lactate dehydrogenase.
19. A yeast strain according to any one of claims 1 to 17 in which the gene coding for lactate dehydrogenase is integrated in the yeast genome.
20. A yeast strain according to any one of claims 1-19

which has been transformed by an expression vector comprising a promoter sequence and a DNA sequence coding for lactate dehydrogenase under the regulation of said promoter sequence.

5 21. A yeast strain according to claim 20 wherein the promoter sequence is a pyruvate decarboxylase gene promoter.

22. A yeast strain according to claim 21 wherein the promoter sequence is a Kluyveromyces pyruvate  
10 decarboxylase gene promoter.

23. A yeast strain according to any one of the preceding claims, overexpressing a lactate transporter.

24. A yeast strain according to claim 23, in which the lactate transporter is JEN1.

15 25. A vector comprising a DNA sequence coding for a lactic dehydrogenase functionally linked to a pyruvate decarboxylase gene promoter.

26. A vector according to claim 25, wherein the promoter sequence is a Kluyveromyces pyruvate decarboxylase gene  
20 promoter.

27. A vector according to claim 26, wherein the promoter sequence is a Kluyveromyces lactis pyruvate decarboxylase gene promoter.

28. A process for the preparation of lactic acid  
25 comprising the growth of a recombinant yeast strain of claims 1-24 in a fermentation medium containing a carbon source and the recovery of lactic acid from the fermentation medium.

29. A process according to claim 28, wherein the carbon  
30 source is selected from one or more of glucose, fructose, galactose, lactose, sucrose, raffinose, maltose,

cellobiose, arabinose, xylose.

30. A process for the preparation of lactic acid according to claim 28 or 29, wherein the fermentation medium contains less than 5 mM of  $Mg^{++}$  and/or less than  
5 0.02 mM of  $Zn^{++}$ .


31. A process according to claims 28-30, wherein the fermentation medium has a pH of 7 or less.

32. A process according to claim 31 wherein the pH is 4.5 or less.

10 33. A process according to claim 32 wherein the pH is 3 or less.


34. A process according to claim 28 for the preparation of D- or L- lactic acid or a mixture of the two.


1/12

**Figure 1**




2/12


**Figure 2**

**Figure 3A**


4/12

**Figure 3B**


5/12

**Figure 4**

6/12

**Figure 5**

7/12

**Figure 6**




Fig 7A




Fig. 7B.




Fig 8.1




Fig. 8.B






Fig. 9A






Fig 9.B.

**Figure 10**

**Figure 11**

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: Biopolo s.c.r.l
- (B) STREET: via gozzi 8
- (C) CITY: Milan
- (E) COUNTRY: Italy
- (F) POSTAL CODE (ZIP): 20129

(ii) TITLE OF INVENTION: Yeats strains for the production of lactic acid

(iii) NUMBER OF SEQUENCES: 4

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(EPO)

## (v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: IT mi97a002080

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTTGCCATTG CTGCAGGCAT CGTGGTG

27

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CCTTTAGGGT CTAGATCCAA GATGGCAAC

29

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CCATGGCAAG TATTACGGAT AAGGATC

27

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CTATCACTGC AGGGTTTCGA TGTC

24

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/05758

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/53 C12N9/04 C12P7/56 //C12N15/31,C07K14/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PORRO D ET AL: "Development of metabolically engineered <i>Saccharomyces cerevisiae</i> cells for the production of lactic acid" BIOTECHNOLOGY PROGRESS, vol. 11, no. 3, May 1995, pages 294-298, XP002091315	1-3,5, 7-12,17, 19,20, 28-31,34
Y	cited in the application see the whole document, paragraph 1 on page 296 in particular  --- -/--	14,16, 18,32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 February 1999

Date of mailing of the international search report

16/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/05758

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE WPI  Week 8849  Derwent Publications Ltd., London, GB;  AN 88-348694  XP002092020  "Production of pyruvic acid by  fermentation - comprises culturing mutant  of <i>Torulopsis</i> with reduced pyruvate  decarboxylase activity"  &amp; JP 63 258586 A (TORAY IND INC)  , 26 October 1988  see abstract</p> <p>---</p>	14, 16
Y	<p>WO 94 00554 A (AGRONOMIQUE INST NAT RECH  ;DEQUIN SYLVIE (FR); BARRE PIERRE (FR))  6 January 1994  cited in the application  see the whole document</p> <p>---</p>	18, 32
A	<p>WO 94 01569 A (RHONE POULENC RORER SA  ;MENART SANDRINE (FR); BOLOTIN MONIQUE  (FR)) 20 January 1994  see abstract</p> <p>---</p>	21, 22
A	<p>DAVIS E ET AL: "A yeast cyclophilin gene  essential for lactate metabolism at high  temperature"  PROCEEDINGS OF THE NATIONAL ACADEMY OF  SCIENCES OF USA,  vol. 89, no. 23, 1 December 1992, pages  11169--11173, XP002092018</p> <p>---</p>	24
A	<p>STEWART J: "Chemist's perspective on the  use of genetically engineered microbes as  reagents for organic synthesis"  BIOTECHNOLOGY AND GENETIC ENGINEERING  REVIEWS,  vol. 14, 1997, pages 67-143, XP002092019  see page 98 - page 100</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05758

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9400554 A	06-01-1994	FR 2692591 A	24-12-1993
		CA 2137824 A	06-01-1994
		EP 0651784 A	10-05-1995
		JP 7508165 T	14-09-1995
		US 5712152 A	27-01-1998
WO 9401569 A	20-01-1994	FR 2693463 A	14-01-1994
		AT 171475 T	15-10-1998
		CA 2139573 A	20-01-1994
		DE 69321235 D	29-10-1998
		EP 0651810 A	10-05-1995
		JP 8500007 T	09-01-1996
		US 5631143 A	20-05-1997